{"id":"follitropin","rwe":[{"pmid":"41901227","year":"2026","title":"Disulfide Bond Mapping of Follitropin Delta, a Recombinant Follicle Stimulating Hormone (rFSH), by X-Ray Crystallography.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41811581","year":"2026","title":"Cost-Effectiveness of Follitropin Delta Compared with Follitropins Alfa and Beta in Controlled Ovarian Stimulation for Assisted Reproductive Technologies (ART) in France.","finding":"","journal":"PharmacoEconomics - open","studyType":"Clinical Study"},{"pmid":"41328812","year":"2026","title":"Real-World Effectiveness and Safety of Recombinant Human Follicle-Stimulating Hormone (rhFSH) in Infertile Women undergoing Assisted Reproductive Technology (ART): A Korean Nationwide Cohort Study.","finding":"","journal":"Clinical pharmacology and therapeutics","studyType":"Clinical Study"},{"pmid":"41327305","year":"2025","title":"A commentary on the article \"Controlled Ovarian Stimulation (COS) with follitropin delta results in higher cumulative live birth rates compared with r-hFSH alfa/beta in a large retrospectively analysed real-world data set\".","finding":"","journal":"Reproductive biology and endocrinology : RB&E","studyType":"Clinical Study"},{"pmid":"41259780","year":"2026","title":"Correction to: Reply: Biosimilars versus the originator of follitropin alfa in ART: eyes wide shut?","finding":"","journal":"Human reproduction (Oxford, England)","studyType":"Clinical Study"}],"_fda":{"id":"102132d6-d45e-4333-badb-7545fa87becc","set_id":"48489027-e52b-4b10-ae74-4ba03839150c","openfda":{"nui":["N0000175838","M0009540"],"unii":["076WHW89TW"],"route":["SUBCUTANEOUS"],"rxcui":["854787","854788","854790","1361563","1361569","1361572"],"spl_id":["102132d6-d45e-4333-badb-7545fa87becc"],"brand_name":["Follistim AQ"],"spl_set_id":["48489027-e52b-4b10-ae74-4ba03839150c"],"package_ndc":["78206-129-99","78206-129-01","78206-129-58","78206-129-59","78206-130-99","78206-130-01","78206-130-58","78206-130-59","78206-131-99","78206-131-01"],"product_ndc":["78206-129","78206-130","78206-131"],"generic_name":["FOLLITROPIN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Gonadotropins [CS]"],"substance_name":["FOLLITROPIN"],"pharm_class_epc":["Gonadotropin [EPC]"],"manufacturer_name":["Organon LLC"],"application_number":["BLA021211"],"is_original_packager":[true]},"version":"10","pregnancy":["8.1 Pregnancy Risk Summary FOLLISTIM AQ Cartridge is contraindicated for use in pregnant women. The incidence of congenital malformations after some Assisted Reproductive Technology, specifically in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)], may be slightly higher than that after spontaneous conception. This slightly higher incidence is thought to be related to differences in parental characteristics (e.g., maternal age, maternal and paternal genetic background, sperm characteristics) and to a higher incidence of multi-fetal gestations after IVF or ICSI [see Warnings and Precautions (5.6) ] . There is no human data that the use of gonadotropins (including FOLLISTIM AQ Cartridge) alone or as part of IVF or ICSI cycles, increases the risk of congenital malformations. The risk of spontaneous abortion (miscarriage) is increased in women who have used gonadotropins products to achieve pregnancy [see Warnings and Precautions (5.8) ] . In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively."],"overdosage":["10 OVERDOSAGE Aside from the possibility of Ovarian Hyperstimulation Syndrome [see Warnings and Precautions (5.2 , 5.3) ] and multiple gestations [see Warnings and Precautions (5.5) ] , there is no additional information concerning the consequences of acute overdosage with FOLLISTIM AQ Cartridge."],"description":["11 DESCRIPTION Follitropin beta, a gonadotropin [human follicle-stimulating hormone (hFSH)], is a glycoprotein hormone produced by recombinant DNA technology in a Chinese hamster ovary (CHO) cell line. It has a dimeric structure containing two glycoprotein subunits (alpha and beta). The alpha and beta subunits have 92 and 111 amino acids, respectively, and their primary and tertiary structures are indistinguishable from that of hFSH. The molecular weight is approximately 40 kDa. FOLLISTIM AQ Cartridge (follitropin beta) injection is a sterile clear and colorless solution, containing either 300 International Units, 600 International Units, or 900 International Units of follitropin beta in disposable single-patient-use cartridges for subcutaneous use only with the FOLLISTIM Pen. Each cartridge delivers 300 International Units in 0.36 mL and the inactive ingredients: benzyl alcohol (3.6 mg; preservative), methionine (0.18 mg), polysorbate 20 (0.072 mg), sodium citrate (4.64 mg), sucrose (18 mg), and Water for Injection USP. Hydrochloric acid NF and/or sodium hydroxide NF are used to adjust the pH to 7. Each cartridge delivers 600 International Units in 0.72 mL and the inactive ingredients: benzyl alcohol (7.2 mg; preservative), methionine (0.36 mg), polysorbate 20 (0.144 mg), sodium citrate (9.3 mg), sucrose (36 mg), and Water for Injection USP. Hydrochloric acid NF and/or sodium hydroxide NF are used to adjust the pH to 7. Each cartridge delivers 900 International Units in 1.08 mL and the inactive ingredients: benzyl alcohol (10.8 mg; preservative), methionine (0.54 mg), polysorbate 20 (0.216 mg), sodium citrate (13.9 mg), sucrose (54 mg), and Water for Injection USP. Hydrochloric acid NF and/or sodium hydroxide NF are used to adjust the pH to 7. Under current storage conditions, FOLLISTIM AQ may contain up to 11% of oxidized follitropin beta."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING FOLLISTIM AQ Cartridge (follitropin beta) injection is a clear and colorless solution in a disposable, prefilled single-patient-use glass cartridge with grey rubber piston and an aluminum crimp-cap with grey rubber inlay supplied in a box containing disposable, 29 gauge, ultra-fine, ½-inch, sterile BD Micro-Fine™ Pen Needles (for use with FOLLISTIM Pen available separately) and in the following presentations: NDC 78206-129-01 FOLLISTIM AQ Cartridge 300 international units per 0.36 mL with silver crimp-caps and 5 BD Micro-Fine Pen Needles NDC 78206-130-01 FOLLISTIM AQ Cartridge 600 international units per 0.72 mL with gold crimp-caps and 7 BD Micro-Fine Pen Needles NDC 78206-131-01 FOLLISTIM AQ Cartridge 900 international units per 1.08 mL with blue crimp-caps and 10 BD Micro-Fine Pen Needles Pharmacy Storage: Store refrigerated 36°F to 46°F (2°C to 8°C) until dispensed. Do not freeze. Patient Storage: Store unused cartridge refrigerated at 36°F to 46°F (2°C to 8°C) until the expiration date, or at room temperature at up to 77°F (25°C) for 3 months or until expiration date, whichever occurs first. After first use, store at 36°F to 77°F (2°C to 25°C) and discard after 28 days. Store in the original carton to protect from light. Do not freeze."],"geriatric_use":["8.5 Geriatric Use Clinical studies of FOLLISTIM AQ Cartridge have not been conducted in patients 65 years of age and older."],"pediatric_use":["8.4 Pediatric Use FOLLISTIM AQ Cartridge is not indicated for use in pediatric patients. Clinical studies have not been conducted in the pediatric population."],"effective_time":"20260224","clinical_studies":["14 CLINICAL STUDIES 14.1 Ovulation Induction The efficacy of FOLLISTIM for ovulation induction was evaluated in a randomized, assessor-blind, parallel-group comparative, multicenter safety and efficacy study of 172 chronic anovulatory women (105 subjects on FOLLISTIM) who had previously failed to ovulate and/or conceive during clomiphene citrate treatment. The study results for ovulation rates are summarized in Table 6 and those for pregnancy rates are summarized in Table 7. Table 6: Cumulative Ovulation Rates Cycle FOLLISTIM (n=105) First treatment cycle 72% Second treatment cycle 82% Third treatment cycle 85% Table 7: Cumulative Ongoing All ongoing pregnancies were confirmed after at least 12 weeks after the hCG injection. , Study was not powered to demonstrate this outcome. Pregnancy Rates Cycle FOLLISTIM (n=105) First treatment cycle 14% Second treatment cycle 19% Third treatment cycle 23% 14.2 Controlled Ovarian Stimulation as Part of an In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI) Cycle The efficacy of FOLLISTIM AQ Cartridge was evaluated in a randomized, double-blind, active-controlled study of 1,509 healthy normal ovulatory women (mean age, body weight, and body mass index of 32 years, 68 kg and 25 kg/m 2 , respectively) treated for one cycle with controlled ovarian stimulation and pituitary suppression with a GnRH antagonist as part of an in vitro fertilization or intracytoplasmic sperm injection cycle. This 2008 study was conducted in Europe and North America (United States and Canada). Approximately 54% of the subjects were from North America. The overall results, as well as the results from North America only, for clinical pregnancy are summarized in Table 8. Table 8: Pregnancy Results from Treatment With FOLLISTIM AQ Cartridge and a GnRH Antagonist in Normal Ovulatory Women Undergoing Controlled Ovarian Stimulation as Part of an In Vitro Fertilization or Intracytoplasmic Sperm Injection Cycle. Single treatment cycle results. Intent-to-Treat Population (ITT) Parameter FOLLISTIM AQ Cartridge Overall data (n=750) FOLLISTIM AQ Cartridge North American data (n=403) Clinical pregnancy rate/cycle initiation Clinical pregnancy was assessed ≥6 weeks after transfer of one or two embryos. 41.1% 48.9% 14.3 Induction of Spermatogenesis The safety and efficacy of FOLLISTIM administered by subcutaneous injection concomitantly with chorionic gonadotropin for injection (hCG) has been examined in a multicenter, open-label, non-comparator clinical study for induction of spermatogenesis in hypogonadotropic hypogonadal men. The study compared the effects of two different FOLLISTIM dosing schedules on semen parameters and serum levels of follicle stimulating hormone (FSH). The multicenter study involved a 16-week pretreatment phase with urinary hCG at a dosage of 1,500 international units twice a week to normalize serum testosterone levels. If serum testosterone levels did not normalize after 8 weeks of hCG treatment, the urinary hCG dose could have been increased to 3,000 international units twice a week. This phase was followed by a 48-week treatment phase. Men who were still azoospermic after the pretreatment phase were randomized to receive either 225 international units FOLLISTIM together with 1,500 international units urinary hCG twice a week or 150 international units FOLLISTIM three times a week together with 1,500 international units urinary hCG twice weekly. Men who required 3,000 international units of urinary hCG twice a week in the pretreatment phase were continued on that dosage during the treatment phase. The mean age of patients in both treatment groups was approximately 30 years (range 18 to 47 years). At baseline, mean left and right testis volumes were 4.61 ± 2.94 mL and 4.57 ± 3.00 mL, respectively, in the group receiving three weekly injections of FOLLISTIM. For the group receiving two weekly injections of FOLLISTIM, the mean left and right testis volumes were 6.54 ± 2.45 mL and 7.21 ± 2.94 mL, respectively, at baseline. The primary efficacy endpoint was the FOLLISTIM percentage of patients with a mean sperm density of ≥1 × 10 6 /mL on their last two treatment assessments. The outcomes of treatment in the 30 men enrolled in the treatment phase are summarized in Table 9. Table 9: Number of Men Receiving FOLLISTIM Who Achieved a Mean Sperm Density of ≥10 6 /mL on Their Last Two Treatment Assessments FOLLISTIM 150 international units three times a week (n=15) FOLLISTIM 225 international units twice a week (n=15) Overall (n=30) Sperm Density of ≥10 6 /mL n % n % n % Yes 6 40 7 47 13 43 No 9 60 8 53 17 57 Overall, the median time to reach a sperm concentration of 10 6 per mL was 165 days (range 25 to 327 days) in patients who demonstrated a sperm concentration of at least 10 6 per mL. The median time to reach a sperm concentration of at least 10 6 per mL was 186 days (range 25 to 327 days) for the 150 international units group and 141 days (range 43 to 204 days) for the 225 international units group. No pregnancy data were collected during the trial. The local tolerance data were comparable between the two treatment groups. The mean percentage of days without pain calculated for all subjects in the treatment period was 91.3% for patients in the 150 international units (three times a week) and 76.0% for patients in the 225 international units (two times a week) FOLLISTIM treatment groups. In the 225 international units (twice per week) group, local symptoms judged as severe by the investigator were: itching in 1 patient (7%), pain in 2 patients (13%), bruising in 2 patients (13%), swelling in 2 patients (13%), and redness in 1 patient (7%). In the 150 international units (three times per week) group, 1 event in 1 patient (bruising, 7%) was judged as severe. No patient discontinued treatment due to injection site reaction or injection site pain."],"laboratory_tests":["5.10 Laboratory Tests For Women : In most instances, treatment with FOLLISTIM AQ Cartridge will result only in follicular growth and maturation. In order to complete the final phase of follicular maturation and to induce ovulation, hCG must be given following the administration of FOLLISTIM AQ Cartridge or when clinical assessment indicates that sufficient follicular maturation has occurred. The degree of follicular maturation and the timing of hCG administration can both be determined with the use of sonographic visualization of the ovaries and endometrial lining in conjunction with measurement of serum estradiol levels. The combination of transvaginal ultrasonography and measurement of serum estradiol levels is also useful for minimizing the risk of OHSS and multi-fetal gestations. The clinical confirmation of ovulation is obtained by the following direct or indirect indices of progesterone production as well as sonographic evidence of ovulation. Direct or indirect indices of progesterone production are: Urinary or serum luteinizing hormone (LH) rise A rise in basal body temperature Increase in serum progesterone Menstruation following the shift in basal body temperature The following provide sonographic evidence of ovulation: Collapsed follicle Fluid in the cul-de-sac Features consistent with corpus luteum formation Sonographic evaluation of the early pregnancy is also important to rule out ectopic pregnancy. For Men : Clinical monitoring for spermatogenesis utilizes the following indirect or direct measures: Serum testosterone level Semen analysis"],"pharmacokinetics":["12.3 Pharmacokinetics Pharmacokinetic parameters for FOLLISTIM AQ Cartridge were evaluated in an open-label, single-center, randomized study in 20 healthy women. Serum FSH values from a single subcutaneous injection of reconstituted FOLLISTIM lyophilized powder administered by conventional syringe were compared to those values following a single subcutaneous injection of FOLLISTIM AQ Cartridge administered with the FOLLISTIM Pen injector. Administration of follitropin beta with the FOLLISTIM Pen resulted an 18% increase in AUC 0–∞ and C max . The 18% difference in serum FSH concentrations resulting from administration of the two formulations was due to differences between the anticipated and actual volume delivered with the conventional syringe. The pharmacokinetic parameters for FOLLISTIM AQ Cartridge are as follows: Table 5: Mean (SD) Pharmacokinetic Parameters of a Single Subcutaneous Injection of 150 IU of FOLLISTIM AQ Cartridge (n=20) AUC 0–∞ (IU/L*h) C max (IU/L) t max (h) t ½ (h) CL app (L/h/kg) AUC 0–∞ Area under the curve C max Maximum concentration t max Time to maximum concentration t ½ Elimination half-life CL app Clearance FOLLISTIM AQ 215.1 3.4 12.9 33.4 0.01 Cartridge (45.8) (0.7) (6.2) (4.2) (0.003) Absorption: Women: The bioavailability of FOLLISTIM following subcutaneous and intramuscular administration was investigated in healthy, pituitary-suppressed women given a single 300 international units dose. In these women, the area under the curve (AUC), expressed as the mean ± SD, was equivalent between the subcutaneous (455.6 ± 141.4 IU*h/L) and intramuscular (445.7 ± 135.7 IU*h/L) routes of administration. However, equivalence could not be established with respect to the peak serum FSH levels (C max ). The C max achieved after subcutaneous administration and intramuscular administration was 5.41 ± 0.72 international units/L and 6.86 ± 2.90 international units/L, respectively. After subcutaneous or intramuscular injection the apparent dose absorbed was 77.8% and 76.4%, respectively. The pharmacokinetics and pharmacodynamics of a single, intramuscular dose (300 international units) of FOLLISTIM were also investigated in a group (n=8) of gonadotropin-deficient, but otherwise healthy women. In these women, FSH (mean ± SD) AUC was 339 ± 105 international units*h/L, C max was 4.3 ± 1.7 international units/L. C max occurred at approximately 27 ± 5.4 hours after intramuscular administration. A multiple dose, dose proportionality, pharmacokinetic study of FOLLISTIM was completed in healthy, pituitary-suppressed, female subjects given subcutaneous doses of 75, 150, or 225 international units for 7 days. Steady-state blood concentrations of FSH were reached with all doses after 5 days of treatment based on the trough concentrations of FSH just prior to dosing (C trough ). Peak blood concentrations with the 75, 150, and 225 international units dose were 4.30 ± 0.60 international units/L, 8.51 ± 1.16 international units/L and 13.92 ± 1.81 international units/L, respectively. Men: No PK studies were conducted using FOLLISTIM AQ Cartridge in men. Exposures of follitropin beta from FOLLISTIM AQ Cartridge and FOLLISTIM are expected to be equivalent after adjusting for the 18% difference in dose [see Dosage and Administration (2) ] . Serum levels of FSH were measured in a clinical study that compared the effects of two different dosing schedules of FOLLISTIM (150 international units three times a week or 225 international units twice a week) administered by subcutaneous injection concurrently with chorionic gonadotropin for induction of spermatogenesis in hypogonadotropic hypogonadal men. Administration of FOLLISTIM was started at Week 17. Mean serum trough concentrations of FSH remained fairly constant over the treatment period. At the end of treatment (Week 64), the mean serum trough concentrations of FSH were 2.09 international units/L in the 150 international units group and 3.22 international units/L in the 225 international units group. Serum trough concentrations of FSH measured prior to the first FOLLISTIM injection on the Mondays of active treatment period (Weeks 17 to 64) and one week after the end of treatment period are presented in Figure 1. Figure 1: Mean (SD) Serum Trough Concentrations of FSH in Men Following Subcutaneous Administration of FOLLISTIM Using Two Different Dosing Schedules (150 International Units Three Times a Week or 225 International Units Twice a Week) Figure 1 Distribution: The volume of distribution of FOLLISTIM in healthy, pituitary-suppressed, women following intravenous administration of a 300 international units dose was approximately 8 L. Metabolism: The recombinant FSH in FOLLISTIM AQ Cartridge is biochemically very similar to urinary FSH and it is therefore anticipated that it is metabolized in the same manner. Elimination: The elimination half-life (t ½ ) following a single subcutaneous injection of 150 IU of FOLLISTIM AQ Cartridge in women was 33.4 (4.2) hours. The clearance was 0.01 (0.003) L/h/kg. Use in Specific Populations : Body weight: The effect of body weight on the pharmacokinetics of FOLLISTIM was evaluated in a group of European and Japanese women who were significantly different in terms of body weight. The European women had a body weight of (mean ± SD) 67.4 ± 13.5 kg and the Japanese subjects were 46.8 ± 11.6 kg. Following a single intramuscular dose of 300 international units of FOLLISTIM, the AUC was significantly smaller in European women (339 ± 105 international units*h/L) than in Japanese women (544 ± 201 international units*h/L). However, clearance per kg of body weight was essentially the same for the respective groups (0.014 and 0.013 L/hr/kg). Geriatric Use: The pharmacokinetics of FOLLISTIM has not been studied in geriatric subjects. Pediatric Use: The pharmacokinetics of FOLLISTIM has not been studied in pediatric subjects. Renal Impairment: The effect of renal impairment on the pharmacokinetics of FOLLISTIM has not been studied. Hepatic Impairment: The effect of hepatic impairment on the pharmacokinetics of FOLLISTIM has not been studied."],"adverse_reactions":["6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling: Abnormal Ovarian Enlargement [see Warnings and Precautions (5.1) ] Ovarian Hyperstimulation Syndrome [see Warnings and Precautions (5.2) ] Atelectasis [see Warnings and Precautions (5.3) ] Thromboembolism [see Warnings and Precautions (5.3) ] Ovarian Torsion [see Warnings and Precautions (5.4) ] Multi-fetal Gestation and Birth [see Warnings and Precautions (5.5) ] Congenital Anomalies [see Warnings and Precautions (5.6) ] Ectopic Pregnancy [see Warnings and Precautions (5.7) ] Spontaneous Abortion [see Warnings and Precautions (5.8) ] Ovarian Neoplasms [see Warnings and Precautions (5.9) ] The most common adverse reactions (≥2%) in women undergoing ovulation induction are ovarian hyperstimulation syndrome, ovarian cyst, abdominal discomfort, abdominal pain and lower abdominal pain. ( 6.1 ) The most common adverse reactions (≥2%) in women undergoing controlled ovarian stimulation as part of an IVF or ICSI cycle are pelvic discomfort, headache, ovarian hyperstimulation syndrome, pelvic pain, nausea and fatigue. ( 6.1 ) The most common (≥2%) adverse reactions in men undergoing induction of spermatogenesis are headache, acne, injection site reaction, injection site pain, gynecomastia, rash and dermoid cyst. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Organon USA LLC, a subsidiary of Organon & Co., at 1-844-674-3200 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Study Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice. Ovulation Induction In a single cycle, multi-center, assessor-blind, parallel group, comparative study, a total of 172 chronic anovulatory women who had failed to ovulate and/or conceive with clomiphene citrate therapy, were randomized and treated with FOLLISTIM (105) or a urofollitropin comparator. Adverse reactions with an incidence of greater than 2% in either treatment group are listed in Table 2. Table 2: Common Adverse Reactions Reported at a Frequency of ≥2% in an Assessor-Blind, Comparative Study of Anovulatory Women Receiving Ovulation Induction System Organ Class/Adverse Reactions Treatment Number (%) of Women FOLLISTIM N=105 n (%) Comparator N=67 n (%) Gastrointestinal disorders Abdominal discomfort 3 (2.9) 1 (1.5) Abdominal pain 3 (2.9) 2 (3.0) Abdominal pain lower 3 (2.9) 1 (1.5) Reproductive system and breast disorders Ovarian cyst 3 (2.9) 2 (3.0) Ovarian hyperstimulation syndrome 8 (7.6) 3 (4.5) General disorders and administration site conditions Pyrexia 0 (0.0) 2 (3.0) Adverse reactions reported commonly (greater than or equal to 2% of women treated with FOLLISTIM) in other ovulation induction clinical trials were headache, abdominal distension, constipation, diarrhea, nausea, pelvic pain, uterine enlargement, vaginal hemorrhage and injection site reaction. In Vitro Fertilization/Intracytoplasmic Sperm Injection In a single cycle, multi-center, double-blind, parallel group, comparative study, a total of 1509 women were randomized to receive controlled ovarian stimulation with either FOLLISTIM AQ Cartridge (751 women were treated with FOLLISTIM AQ Cartridge) or a comparator and pituitary suppression with a gonadotropin releasing hormone (GnRH) antagonist as part of an in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycle. Table 3 lists adverse reactions with an incidence of greater than 2% in the group of women treated with FOLLISTIM AQ Cartridge. Table 3: Common Adverse Reactions Reported at a Frequency of ≥2% in a Randomized, Double-blind, Active-controlled, Comparative Study of Normal Ovulatory Women Undergoing Controlled Ovarian Stimulation as Part of an In Vitro Fertilization or Intracytoplasmic Sperm Injection Cycle System Organ Class/Adverse Reactions FOLLISTIM AQ Cartridge Treatment N = 751 n n a = number of women with the adverse reaction. (%) Nervous System disorders Headache 55 (7.3%) Gastrointestinal disorders Nausea 29 (3.9%) Reproductive system and breast disorders Ovarian Hyperstimulation Syndrome 48 (6.4%) Pelvic discomfort 62 (8.3%) Pelvic Pain 41 (5.5%) General disorders and Administration site conditions Fatigue 17 (2.3%) Induction of Spermatogenesis In an open-label, non-comparative clinical trial, 49 men with hypogonadotropic hypogonadism were enrolled to receive pretreatment with hCG, followed by combination therapy with hCG and FOLLISTIM for induction of spermatogenesis. Of the 49 men, 30 received weekly FOLLISTIM doses of 450 international units; 24 of these 30 men received a total of 48 weeks of treatment with FOLLISTIM. Adverse reactions occurring with an incidence of greater than 2% in the 30 men treated with FOLLISTIM are listed in Table 4. Table 4: Common Adverse Reactions Reported at a Frequency of ≥2% in an Open-Label Clinical Trial in Men with Hypogonadotropic Hypogonadism System Organ Class/Adverse Reactions FOLLISTIM Treatment N=30 n (%) Nervous system disorders Headache 2 (6.7) General disorders and administration site disorders Injection site reaction 2 (6.7) Injection site pain 2 (6.7) Skin and cutaneous tissue disorders Acne 2 (6.7) Rash 1 (3.3) Reproductive system and breast disorders Gynecomastia 1 (3.3) Neoplasms benign, malignant and unspecified Dermoid cyst 1 (3.3) 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of FOLLISTIM and/or FOLLISTIM AQ Cartridge. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Gastrointestinal disorders Abdominal distension, abdominal pain, constipation, diarrhea General disorders and administration site conditions Injection site reaction Immune system disorders Hypersensitivity reactions including anaphylaxis, pruritus, rash, and urticaria Reproductive system and breast disorders Breast tenderness, metrorrhagia, ovarian enlargement, vaginal hemorrhage Skin and subcutaneous tissue disorders Rash Vascular disorders Thromboembolism [see Warnings and Precautions (5.3) ]"],"contraindications":["4 CONTRAINDICATIONS FOLLISTIM AQ Cartridge is contraindicated in women and men who exhibit: Prior hypersensitivity to recombinant hFSH products or any component of FOLLISTIM AQ Cartridge. Reactions including anaphylaxis have been reported [see Adverse Reactions (6.2) ] High levels of FSH indicating primary gonadal failure Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders) [see Indications and Usage (1.1 , 1.2 , 1.3) ] Hypersensitivity reactions to streptomycin or neomycin. FOLLISTIM AQ may contain traces of these antibiotics Tumors of the ovary, breast, uterus, testis, hypothalamus or pituitary gland FOLLISTIM AQ Cartridge is also contraindicated in women who exhibit: Pregnancy [see Use in Specific Populations (8.1) ] Heavy or irregular vaginal bleeding of undetermined origin Ovarian cysts or enlargement not due to polycystic ovary syndrome (PCOS) Women and men who exhibit: Prior hypersensitivity to recombinant hFSH products ( 4 ) High levels of FSH indicating primary gonadal failure ( 4 ) Presence of uncontrolled non-gonadal endocrinopathies ( 4 ) Hypersensitivity reactions related to streptomycin or neomycin ( 4 ) Tumors of the ovary, breast, uterus, testis, hypothalamus or pituitary gland ( 4 ) Women who exhibit: Pregnancy ( 4 , 8.1 ) Heavy or irregular vaginal bleeding of undetermined origin ( 4 ) Ovarian cysts or enlargement not due to polycystic ovary syndrome (PCOS) ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS No drug-drug interaction studies have been performed."],"mechanism_of_action":["12.1 Mechanism of Action Women: Follicle-stimulating hormone (FSH), the active component in FOLLISTIM AQ Cartridge, is required for normal follicular growth, maturation, and gonadal steroid production. In women, the level of FSH is critical for the onset and duration of follicular development, and consequently for the timing and number of follicles reaching maturity. FOLLISTIM AQ Cartridge stimulates ovarian follicular growth in women who do not have primary ovarian failure. In order to effect the final phase of follicle maturation, resumption of meiosis and rupture of the follicle in the absence of an endogenous LH surge, human chorionic gonadotropin (hCG) must be given following treatment with FOLLISTIM AQ Cartridge when patient monitoring indicates appropriate follicular development parameters have been reached. Men: FOLLISTIM when administered with hCG stimulates spermatogenesis in men with hypogonadotropic hypogonadism. FSH, the active component of FOLLISTIM, is the pituitary hormone responsible for spermatogenesis."],"storage_and_handling":["Pharmacy Storage: Store refrigerated 36°F to 46°F (2°C to 8°C) until dispensed. Do not freeze. Patient Storage: Store unused cartridge refrigerated at 36°F to 46°F (2°C to 8°C) until the expiration date, or at room temperature at up to 77°F (25°C) for 3 months or until expiration date, whichever occurs first. After first use, store at 36°F to 77°F (2°C to 25°C) and discard after 28 days. Store in the original carton to protect from light. Do not freeze."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Women: Follicle-stimulating hormone (FSH), the active component in FOLLISTIM AQ Cartridge, is required for normal follicular growth, maturation, and gonadal steroid production. In women, the level of FSH is critical for the onset and duration of follicular development, and consequently for the timing and number of follicles reaching maturity. FOLLISTIM AQ Cartridge stimulates ovarian follicular growth in women who do not have primary ovarian failure. In order to effect the final phase of follicle maturation, resumption of meiosis and rupture of the follicle in the absence of an endogenous LH surge, human chorionic gonadotropin (hCG) must be given following treatment with FOLLISTIM AQ Cartridge when patient monitoring indicates appropriate follicular development parameters have been reached. Men: FOLLISTIM when administered with hCG stimulates spermatogenesis in men with hypogonadotropic hypogonadism. FSH, the active component of FOLLISTIM, is the pituitary hormone responsible for spermatogenesis. 12.3 Pharmacokinetics Pharmacokinetic parameters for FOLLISTIM AQ Cartridge were evaluated in an open-label, single-center, randomized study in 20 healthy women. Serum FSH values from a single subcutaneous injection of reconstituted FOLLISTIM lyophilized powder administered by conventional syringe were compared to those values following a single subcutaneous injection of FOLLISTIM AQ Cartridge administered with the FOLLISTIM Pen injector. Administration of follitropin beta with the FOLLISTIM Pen resulted an 18% increase in AUC 0–∞ and C max . The 18% difference in serum FSH concentrations resulting from administration of the two formulations was due to differences between the anticipated and actual volume delivered with the conventional syringe. The pharmacokinetic parameters for FOLLISTIM AQ Cartridge are as follows: Table 5: Mean (SD) Pharmacokinetic Parameters of a Single Subcutaneous Injection of 150 IU of FOLLISTIM AQ Cartridge (n=20) AUC 0–∞ (IU/L*h) C max (IU/L) t max (h) t ½ (h) CL app (L/h/kg) AUC 0–∞ Area under the curve C max Maximum concentration t max Time to maximum concentration t ½ Elimination half-life CL app Clearance FOLLISTIM AQ 215.1 3.4 12.9 33.4 0.01 Cartridge (45.8) (0.7) (6.2) (4.2) (0.003) Absorption: Women: The bioavailability of FOLLISTIM following subcutaneous and intramuscular administration was investigated in healthy, pituitary-suppressed women given a single 300 international units dose. In these women, the area under the curve (AUC), expressed as the mean ± SD, was equivalent between the subcutaneous (455.6 ± 141.4 IU*h/L) and intramuscular (445.7 ± 135.7 IU*h/L) routes of administration. However, equivalence could not be established with respect to the peak serum FSH levels (C max ). The C max achieved after subcutaneous administration and intramuscular administration was 5.41 ± 0.72 international units/L and 6.86 ± 2.90 international units/L, respectively. After subcutaneous or intramuscular injection the apparent dose absorbed was 77.8% and 76.4%, respectively. The pharmacokinetics and pharmacodynamics of a single, intramuscular dose (300 international units) of FOLLISTIM were also investigated in a group (n=8) of gonadotropin-deficient, but otherwise healthy women. In these women, FSH (mean ± SD) AUC was 339 ± 105 international units*h/L, C max was 4.3 ± 1.7 international units/L. C max occurred at approximately 27 ± 5.4 hours after intramuscular administration. A multiple dose, dose proportionality, pharmacokinetic study of FOLLISTIM was completed in healthy, pituitary-suppressed, female subjects given subcutaneous doses of 75, 150, or 225 international units for 7 days. Steady-state blood concentrations of FSH were reached with all doses after 5 days of treatment based on the trough concentrations of FSH just prior to dosing (C trough ). Peak blood concentrations with the 75, 150, and 225 international units dose were 4.30 ± 0.60 international units/L, 8.51 ± 1.16 international units/L and 13.92 ± 1.81 international units/L, respectively. Men: No PK studies were conducted using FOLLISTIM AQ Cartridge in men. Exposures of follitropin beta from FOLLISTIM AQ Cartridge and FOLLISTIM are expected to be equivalent after adjusting for the 18% difference in dose [see Dosage and Administration (2) ] . Serum levels of FSH were measured in a clinical study that compared the effects of two different dosing schedules of FOLLISTIM (150 international units three times a week or 225 international units twice a week) administered by subcutaneous injection concurrently with chorionic gonadotropin for induction of spermatogenesis in hypogonadotropic hypogonadal men. Administration of FOLLISTIM was started at Week 17. Mean serum trough concentrations of FSH remained fairly constant over the treatment period. At the end of treatment (Week 64), the mean serum trough concentrations of FSH were 2.09 international units/L in the 150 international units group and 3.22 international units/L in the 225 international units group. Serum trough concentrations of FSH measured prior to the first FOLLISTIM injection on the Mondays of active treatment period (Weeks 17 to 64) and one week after the end of treatment period are presented in Figure 1. Figure 1: Mean (SD) Serum Trough Concentrations of FSH in Men Following Subcutaneous Administration of FOLLISTIM Using Two Different Dosing Schedules (150 International Units Three Times a Week or 225 International Units Twice a Week) Figure 1 Distribution: The volume of distribution of FOLLISTIM in healthy, pituitary-suppressed, women following intravenous administration of a 300 international units dose was approximately 8 L. Metabolism: The recombinant FSH in FOLLISTIM AQ Cartridge is biochemically very similar to urinary FSH and it is therefore anticipated that it is metabolized in the same manner. Elimination: The elimination half-life (t ½ ) following a single subcutaneous injection of 150 IU of FOLLISTIM AQ Cartridge in women was 33.4 (4.2) hours. The clearance was 0.01 (0.003) L/h/kg. Use in Specific Populations : Body weight: The effect of body weight on the pharmacokinetics of FOLLISTIM was evaluated in a group of European and Japanese women who were significantly different in terms of body weight. The European women had a body weight of (mean ± SD) 67.4 ± 13.5 kg and the Japanese subjects were 46.8 ± 11.6 kg. Following a single intramuscular dose of 300 international units of FOLLISTIM, the AUC was significantly smaller in European women (339 ± 105 international units*h/L) than in Japanese women (544 ± 201 international units*h/L). However, clearance per kg of body weight was essentially the same for the respective groups (0.014 and 0.013 L/hr/kg). Geriatric Use: The pharmacokinetics of FOLLISTIM has not been studied in geriatric subjects. Pediatric Use: The pharmacokinetics of FOLLISTIM has not been studied in pediatric subjects. Renal Impairment: The effect of renal impairment on the pharmacokinetics of FOLLISTIM has not been studied. Hepatic Impairment: The effect of hepatic impairment on the pharmacokinetics of FOLLISTIM has not been studied."],"indications_and_usage":["1 INDICATIONS AND USAGE FOLLISTIM ® AQ Cartridge (follitropin beta) injection, is indicated: In Women for: FOLLISTIM AQ Cartridge is a gonadotropin indicated: In Women for: Induction of Ovulation and Pregnancy in Anovulatory Infertile Women in Whom the Cause of Infertility is Functional and Not Due to Primary Ovarian Failure ( 1.1 ) Pregnancy in Normal Ovulatory Women Undergoing Controlled Ovarian Stimulation as Part of an In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI) Cycle ( 1.2 ) In Men for: Induction of Spermatogenesis in Men with Primary and Secondary Hypogonadotropic Hypogonadism (HH) in Whom the Cause of Infertility is Not Due to Primary Testicular Failure ( 1.3 ) 1.1 Induction of Ovulation and Pregnancy in Anovulatory Infertile Women in Whom the Cause of Infertility is Functional and Not Due to Primary Ovarian Failure Prior to initiation of treatment with FOLLISTIM AQ Cartridge: Women should have a complete gynecologic and endocrinologic evaluation. Primary ovarian failure should be excluded. The possibility of pregnancy should be excluded. Tubal patency should be demonstrated. The fertility status of the male partner should be evaluated. 1.2 Pregnancy in Normal Ovulatory Women Undergoing Controlled Ovarian Stimulation as Part of an In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI) Cycle Prior to initiation of treatment with FOLLISTIM AQ Cartridge: Women should have a complete gynecologic and endocrinologic evaluation and diagnosis of cause of infertility. The possibility of pregnancy should be excluded. The fertility status of the male partner should be evaluated. In Men for: 1.3 Induction of Spermatogenesis in Men with Primary and Secondary Hypogonadotropic Hypogonadism (HH) in Whom the Cause of Infertility is Not Due to Primary Testicular Failure Prior to initiation of treatment with FOLLISTIM AQ Cartridge: Men should have a complete medical and endocrinologic evaluation. Hypogonadotropic hypogonadism should be confirmed and primary testicular failure should be excluded. Serum testosterone levels should be normalized with human chorionic gonadotropin (hCG) treatment. The fertility status of the female partner should be evaluated."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS FOLLISTIM AQ Cartridge should be used only by physicians who are experienced in infertility treatment. FOLLISTIM AQ Cartridge contains a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) [see Warnings and Precautions (5.2) ] with or without pulmonary or vascular complications [see Warnings and Precautions (5.3) ] and multiple births [see Warnings and Precautions (5.5) ] . Gonadotropin therapy requires the availability of appropriate monitoring facilities [see Warnings and Precautions (5.10) ] . Careful attention should be given to the diagnosis of infertility and in the selection of candidates for FOLLISTIM AQ Cartridge therapy [see Indications and Usage (1.1 , 1.2 , 1.3) and Dosage and Administration (2.2 , 2.3 , 2.4) ] . Switching to FOLLISTIM AQ Cartridge from other brands (manufacturer), types (recombinant, urinary), and/or methods of administration (FOLLISTIM Pen, conventional syringe) may necessitate an adjustment of the dose [see Dosage and Administration (2) ] . Treatment with FOLLISTIM AQ may result in: Abnormal Ovarian Enlargement ( 5.1 ) Ovarian Hyperstimulation Syndrome (OHSS) ( 5.2 ) Pulmonary and Vascular Complications ( 5.3 ) Ovarian Torsion ( 5.4 ) Multi-fetal Gestation and Birth ( 5.5 ) Congenital Anomalies ( 5.6 ) Ectopic Pregnancy ( 5.7 ) Spontaneous Abortion ( 5.8 ) Ovarian Neoplasms ( 5.9 ) 5.1 Abnormal Ovarian Enlargement In order to minimize the hazards associated with abnormal ovarian enlargement that may occur with FOLLISTIM AQ therapy, treatment should be individualized and the lowest effective dose should be used [ see Dosage and Administration (2.2 , 2.3) ] . Use of ultrasound monitoring of ovarian response and/or measurement of serum estradiol levels is important to minimize the risk of overstimulation [see Warnings and Precautions (5.8) ] . If the ovaries are abnormally enlarged on the last day of FOLLISTIM AQ therapy, hCG should not be administered in order to reduce the chances of developing Ovarian Hyperstimulation Syndrome (OHSS). Intercourse should be prohibited in patients with significant ovarian enlargement after ovulation because of the danger of hemoperitoneum resulting from ruptured ovarian cysts [see Warnings and Precautions (5.3) ] . 5.2 Ovarian Hyperstimulation Syndrome (OHSS) OHSS is a medical entity distinct from uncomplicated ovarian enlargement and may progress rapidly to become a serious medical condition. OHSS is characterized by a dramatic increase in vascular permeability, which can result in a rapid accumulation of fluid in the peritoneal cavity, thorax, and potentially, the pericardium. The early warning signs of OHSS developing are severe pelvic pain, nausea, vomiting, and weight gain. Abdominal pain, abdominal distension, gastrointestinal symptoms including nausea, vomiting and diarrhea, severe ovarian enlargement, weight gain, dyspnea, and oliguria have been reported with OHSS. Clinical evaluation may reveal hypovolemia, hemoconcentration, electrolyte imbalances, ascites, hemoperitoneum, pleural effusions, hydrothorax, acute pulmonary distress, and thromboembolic reactions [see Warnings and Precautions (5.3) ] . Transient liver function test abnormalities suggestive of hepatic dysfunction with or without morphologic changes on liver biopsy have also been reported in association with OHSS. OHSS occurs after gonadotropin treatment has been discontinued, and it can develop rapidly, reaching its maximum about seven to ten days following treatment. Usually, OHSS resolves spontaneously with the onset of menses. If there is a risk for OHSS evident prior to hCG administration [see Warnings and Precautions (5.1) ] , the hCG must be withheld. Cases of OHSS are more common, more severe, and more protracted if pregnancy occurs; therefore, women should be assessed for the development of OHSS for at least two weeks after hCG administration. If serious OHSS occurs, gonadotropins, including hCG, should be stopped and consideration should be given as to whether the patient needs to be hospitalized. Treatment is primarily symptomatic and overall should consist of bed rest, fluid and electrolyte management, and analgesics (if needed). Because the use of diuretics can accentuate the diminished intravascular volume, diuretics should be avoided except in the late phase of resolution as described below. The management of OHSS may be divided into three phases as follows: Acute Phase: Management should be directed at preventing hemoconcentration due to loss of intravascular volume to the third space and minimizing the risk of thromboembolic phenomena and kidney damage. Fluid intake and output, weight, hematocrit, serum and urinary electrolytes, urine specific gravity, BUN and creatinine, total proteins with albumin: globulin ratio, coagulation studies, electrocardiogram to monitor for hyperkalemia, and abdominal girth should be thoroughly assessed daily or more often based on the clinical need. Treatment, consisting of limited intravenous fluids, electrolytes, and human serum albumin is intended to normalize electrolytes while maintaining an acceptable but somewhat reduced intravascular volume. Full correction of the intravascular volume deficit may lead to an unacceptable increase in the amount of third space fluid accumulation. Chronic Phase: After the acute phase is successfully managed as above, excessive fluid accumulation in the third space should be limited by instituting severe potassium, sodium, and fluid restriction. Resolution Phase: As third space fluid returns to the intravascular compartment, a fall in hematocrit and increasing urinary output are observed in the absence of any increase in intake. Peripheral and/or pulmonary edema may result if the kidneys are unable to excrete third space fluid as rapidly as it is mobilized. Diuretics may be indicated during the resolution phase, if necessary, to combat pulmonary edema. OHSS increases the risk of injury to the ovary. The ascitic, pleural, and pericardial fluid should not be removed unless there is the necessity to relieve symptoms such as pulmonary distress or cardiac tamponade. Pelvic examination may cause rupture of an ovarian cyst, which may result in hemoperitoneum, and should therefore be avoided. If bleeding occurs and requires surgical intervention, the clinical objective should be to control the bleeding and retain as much ovarian tissue as possible. During clinical trials with FOLLISTIM or FOLLISTIM AQ Cartridge therapy, OHSS occurred in 7.6% of 105 women (OI) and 6.4% of 751 women (IVF or ICSI) treated with FOLLISTIM and FOLLISTIM AQ Cartridge, respectively. 5.3 Pulmonary and Vascular Complications Serious pulmonary conditions (e.g., atelectasis, acute respiratory distress syndrome) have been reported in women treated with gonadotropins. In addition, thromboembolic reactions both in association with, and separate from OHSS have been reported following gonadotropin therapy. Intravascular thrombosis, which may originate in venous or arterial vessels, can result in reduced blood flow to vital organs or the extremities. Women with generally recognized risk factors for thrombosis, such as a personal or family history, severe obesity, or thrombophilia, may have an increased risk of venous or arterial thromboembolic events, during or following treatment with gonadotropins. Sequelae of such reactions have included venous thrombophlebitis, pulmonary embolism, pulmonary infarction, cerebral vascular occlusion (stroke), and arterial occlusion resulting in loss of limb and rarely in myocardial infarction. In rare cases, pulmonary complications and/or thromboembolic reactions have resulted in death. In women with recognized risk factors, the benefits of ovulation induction, in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment need to be weighed against the risks. It should be noted that pregnancy itself also carries an increased risk of thrombosis. 5.4 Ovarian Torsion Ovarian torsion has been reported after treatment with FOLLISTIM AQ Cartridge and after intervention with other gonadotropins. This may be related to OHSS, pregnancy, previous abdominal surgery, past history of ovarian torsion, previous or current ovarian cyst and polycystic ovaries. Damage to the ovary due to reduced blood supply can be limited by early diagnosis and immediate detorsion. 5.5 Multi-fetal Gestation and Birth Multi-fetal gestation and births have been reported with all gonadotropin treatments including FOLLISTIM AQ Cartridge treatment. The woman and her partner should be advised of the potential risk of multi-fetal gestation and births before starting treatment. 5.6 Congenital Anomalies The incidence of congenital malformations after IVF or ICSI may be slightly higher than after spontaneous conception. This slightly higher incidence is thought to be related to differences in parental characteristics (e.g., maternal age, sperm characteristics) and to the higher incidence of multi-fetal gestations after IVF or ICSI. There are no indications that the use of gonadotropins during IVF or ICSI is associated with an increased risk of congenital malformations. 5.7 Ectopic Pregnancy Since infertile women undergoing IVF or ICSI often have tubal abnormalities, the incidence of ectopic pregnancies might be increased. Early confirmation of an intrauterine pregnancy should be determined by β-hCG testing and transvaginal ultrasound. 5.8 Spontaneous Abortion The risk of spontaneous abortions (miscarriage) is increased with gonadotropin products. However, causality has not been established. The increased risk may be a factor of the underlying infertility. 5.9 Ovarian Neoplasms There have been infrequent reports of ovarian neoplasms, both benign and malignant, in women who have undergone multiple drug regimens for controlled ovarian stimulation; however, a causal relationship has not been established. 5.10 Laboratory Tests For Women : In most instances, treatment with FOLLISTIM AQ Cartridge will result only in follicular growth and maturation. In order to complete the final phase of follicular maturation and to induce ovulation, hCG must be given following the administration of FOLLISTIM AQ Cartridge or when clinical assessment indicates that sufficient follicular maturation has occurred. The degree of follicular maturation and the timing of hCG administration can both be determined with the use of sonographic visualization of the ovaries and endometrial lining in conjunction with measurement of serum estradiol levels. The combination of transvaginal ultrasonography and measurement of serum estradiol levels is also useful for minimizing the risk of OHSS and multi-fetal gestations. The clinical confirmation of ovulation is obtained by the following direct or indirect indices of progesterone production as well as sonographic evidence of ovulation. Direct or indirect indices of progesterone production are: Urinary or serum luteinizing hormone (LH) rise A rise in basal body temperature Increase in serum progesterone Menstruation following the shift in basal body temperature The following provide sonographic evidence of ovulation: Collapsed follicle Fluid in the cul-de-sac Features consistent with corpus luteum formation Sonographic evaluation of the early pregnancy is also important to rule out ectopic pregnancy. For Men : Clinical monitoring for spermatogenesis utilizes the following indirect or direct measures: Serum testosterone level Semen analysis 5.11 FOLLISTIM Pen The FOLLISTIM Pen is intended only for use with FOLLISTIM AQ Cartridge. The FOLLISTIM Pen is not recommended for the blind or visually impaired without the assistance of an individual with good vision who is trained in the proper use of the injection device."],"clinical_studies_table":["
Table 6: Cumulative Ovulation Rates
CycleFOLLISTIM (n=105)
First treatment cycle72%
Second treatment cycle82%
Third treatment cycle85%
","
Table 7: Cumulative OngoingAll ongoing pregnancies were confirmed after at least 12 weeks after the hCG injection., Study was not powered to demonstrate this outcome. Pregnancy Rates
CycleFOLLISTIM (n=105)
First treatment cycle14%
Second treatment cycle19%
Third treatment cycle23%
","
Table 8: Pregnancy Results from Treatment With FOLLISTIM AQ Cartridge and a GnRH Antagonist in Normal Ovulatory Women Undergoing Controlled Ovarian Stimulation as Part of an In Vitro Fertilization or Intracytoplasmic Sperm Injection Cycle.Single treatment cycle results. Intent-to-Treat Population (ITT)
ParameterFOLLISTIM AQ Cartridge Overall data (n=750)FOLLISTIM AQ Cartridge North American data (n=403)
Clinical pregnancy rate/cycle initiationClinical pregnancy was assessed ≥6 weeks after transfer of one or two embryos.41.1%48.9%
","
Table 9: Number of Men Receiving FOLLISTIM Who Achieved a Mean Sperm Density of ≥106/mL on Their Last Two Treatment Assessments
FOLLISTIM 150 international units three times a week (n=15)FOLLISTIM 225 international units twice a week (n=15)Overall (n=30)
Sperm Density of ≥106/mL n%n%n%
Yes6407471343
No9608531757
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term toxicity studies in animals have not been performed with FOLLISTIM to evaluate the carcinogenic potential of the drug. FOLLISTIM was not mutagenic in the Ames test using S. typhimurium and E. coli tester strains and did not produce chromosomal aberrations in an in vitro assay using human lymphocytes."],"pharmacokinetics_table":["
Table 5: Mean (SD) Pharmacokinetic Parameters of a Single Subcutaneous Injection of 150 IU of FOLLISTIM AQ Cartridge (n=20)
AUC0–∞ (IU/L*h)Cmax (IU/L)tmax (h)t½ (h)CLapp (L/h/kg)
AUC0–∞ Area under the curve Cmax Maximum concentration tmax Time to maximum concentration t½ Elimination half-life CLapp Clearance
FOLLISTIM AQ215.13.412.933.40.01
Cartridge(45.8)(0.7)(6.2)(4.2)(0.003)
","
Figure 1: Mean (SD) Serum Trough Concentrations of FSH in Men Following Subcutaneous Administration of FOLLISTIM Using Two Different Dosing Schedules (150 International Units Three Times a Week or 225 International Units Twice a Week)
"],"adverse_reactions_table":["
Table 2: Common Adverse Reactions Reported at a Frequency of ≥2% in an Assessor-Blind, Comparative Study of Anovulatory Women Receiving Ovulation Induction
System Organ Class/Adverse ReactionsTreatment Number (%) of Women
FOLLISTIM N=105 n (%)Comparator N=67 n (%)
Gastrointestinal disorders
Abdominal discomfort3 (2.9)1 (1.5)
Abdominal pain3 (2.9)2 (3.0)
Abdominal pain lower3 (2.9)1 (1.5)
Reproductive system and breast disorders
Ovarian cyst3 (2.9)2 (3.0)
Ovarian hyperstimulation syndrome8 (7.6)3 (4.5)
General disorders and administration site conditions
Pyrexia0 (0.0)2 (3.0)
","
Table 3: Common Adverse Reactions Reported at a Frequency of ≥2% in a Randomized, Double-blind, Active-controlled, Comparative Study of Normal Ovulatory Women Undergoing Controlled Ovarian Stimulation as Part of an In Vitro Fertilization or Intracytoplasmic Sperm Injection Cycle
System Organ Class/Adverse ReactionsFOLLISTIM AQ Cartridge Treatment N = 751 nna = number of women with the adverse reaction. (%)
Nervous System disorders
Headache55 (7.3%)
Gastrointestinal disorders
Nausea29 (3.9%)
Reproductive system and breast disorders
Ovarian Hyperstimulation Syndrome48 (6.4%)
Pelvic discomfort62 (8.3%)
Pelvic Pain41 (5.5%)
General disorders and Administration site conditions
Fatigue17 (2.3%)
","
Table 4: Common Adverse Reactions Reported at a Frequency of ≥2% in an Open-Label Clinical Trial in Men with Hypogonadotropic Hypogonadism
System Organ Class/Adverse ReactionsFOLLISTIM Treatment N=30 n (%)
Nervous system disorders
Headache2 (6.7)
General disorders and administration site disorders
Injection site reaction2 (6.7)
Injection site pain2 (6.7)
Skin and cutaneous tissue disorders
Acne2 (6.7)
Rash1 (3.3)
Reproductive system and breast disorders
Gynecomastia1 (3.3)
Neoplasms benign, malignant and unspecified
Dermoid cyst1 (3.3)
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Patient Information ). Hypersensitivity Reactions and Anaphylaxis Advise patients to discontinue FOLLISTIM AQ Cartridge and seek immediate medical attention if any signs or symptoms of a hypersensitivity reaction occur [see Contraindications (4) and Adverse Reactions (6.2) ] . Dosing and Use of FOLLISTIM AQ Cartridge with Pen Instruct women and men on the correct usage and dosing of FOLLISTIM AQ Cartridge in conjunction with the FOLLISTIM Pen. Make sure that individuals who have used other gonadotropin products delivered by a syringe are aware of differences arising from use of the pen. Women and men should read and follow all instructions in the FOLLISTIM Pen \" Instructions for Use \" Manual prior to administration of FOLLISTIM AQ Cartridge. Advise women and men of the number of doses which can be extracted from the full unused FOLLISTIM AQ Cartridge that you have prescribed. Therapy Duration and Necessary Monitoring in Women and Men Undergoing Treatment Prior to beginning therapy with FOLLISTIM AQ Cartridge, inform women and men about the time commitment and monitoring procedures necessary to undergo treatment [see Dosage and Administration (2) , Warnings and Precautions (5.10) ] . Instructions on a Missed Dose Inform women and men that if they miss or forget to take a dose of FOLLISTIM AQ Cartridge, the next dose should not be doubled and they should call the healthcare provider for further dosing instructions. Ovarian Hyperstimulation Syndrome Inform women regarding the risks with use of FOLLISTIM AQ Cartridge of Ovarian Hyperstimulation Syndrome [see Warnings and Precautions (5.2) ] and associated symptoms including lung and blood vessel problems [see Warnings and Precautions (5.3) ] and ovarian torsion [see Warnings and Precautions (5.4) ] . Multi-fetal Gestation and Birth Inform women regarding the risk of multi-fetal gestations with the use of FOLLISTIM AQ Cartridge [see Warnings and Precautions (5.5) ] ."],"spl_unclassified_section":["Manufactured by: Organon USA LLC, a subsidiary of ORGANON & Co., Jersey City, NJ 07302, USA U.S. License No.2331 BD, BD Logo and BD Micro-Fine are trademarks of Becton, Dickinson and Company. For patent information: www.organon.com/our-solutions/patent/ © 2026 Organon group of companies. All rights reserved. uspi-og8328-SOi-2602r001","INSTRUCTIONS FOR USE FOLLISTIM ® (Fol΄-lis-tim) AQ Cartridge (follitropin beta) injection, for subcutaneous use Read this Instructions for Use before you start using FOLLISTIM ® AQ Cartridge and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment. Important Information FOLLISTIM AQ Cartridge is injected subcutaneously (beneath the skin) only. FOLLISTIM AQ Cartridge is for single-patient-use only. FOLLISTIM AQ Cartridge is used with FOLLISTIM Pen (supplied separately). FOLLISTIM Pen is not recommended for use by the blind or visually impaired without the help of a person trained to use the injection device. Learn about all of the parts of the FOLLISTIM Pen (See Figure 1 ), FOLLISTIM AQ Cartridge (See Figure 2 ) and the BD Micro-Fine™ Pen Needle (See Figure 3 ). The BD Micro-Fine™ Pen Needle is for use only with the FOLLISTIM AQ Cartridge. Each needle is for 1 injection only. Do not add any other medicine to the FOLLISTIM AQ Cartridge. Be very careful when handling the needle. If you are giving an injection to another person, accidental needle sticks with used needles can cause serious infections or infections that may lead to death. Storing FOLLISTIM AQ Cartridge Store unused FOLLISTIM AQ Cartridge in the refrigerator between 36°F to 46°F (2°C to 8°C) until the expiration date. If needed, FOLLISTIM AQ Cartridge can be stored at room temperature up to 77°F (25°C) for 3 months or until the expiration date, whichever comes first. After first use, store FOLLISTIM AQ Cartridge either in the refrigerator or at room temperature between 36°F to 77°F (2°C to 25°C). Throw away after 28 days, even if there is still medicine in the FOLLISTIM AQ Cartridge. Keep FOLLISTIM AQ Cartridge in the original carton to protect from light. Do not freeze. Figure 1. FOLLISTIM Pen and its Parts Figure 2. Parts of FOLLISTIM AQ Cartridge Figure 3. Parts of BD Micro-Fine Pen Needle Unit A. Getting Ready Remove the FOLLISTIM AQ Cartridge out of the refrigerator. Injecting cold medicine can cause discomfort at the injection site. Allow the FOLLISTIM AQ Cartridge to reach room temperature before injecting. Check the liquid in the cartridge to make sure it is clear and colorless. Do not use , if the liquid is not clear and colorless or has particles in it . Gather the supplies you will need for your injection. You will need: a clean dry surface FOLLISTIM Pen FOLLISTIM AQ Cartridge BD Micro-Fine Pen Needle alcohol pads cotton balls or sterile gauze a puncture-proof container to throw away the used cartridge and needle Wash your hands with soap and water and dry them before you use FOLLISTIM Pen and when you replace the cartridge. B. Loading the FOLLISTIM Pen with the FOLLISTIM AQ Cartridge Hold the FOLLISTIM Pen Body firmly with one hand. With the other hand, pull the Protective Cap straight off with your other hand (See Figure 4 ). Put the cap aside on a clean, dry surface. Figure 4 Unscrew the Pen Body from the Cartridge Holder (See Figure 5 ). Place the Cartridge Holder and the Pen Body aside. Figure 5 Take the FOLLISTIM AQ Cartridge out of the package. Clean the rubber inlay on the cartridge with an alcohol pad. Put the FOLLISTIM AQ Cartridge into the Cartridge Holder (See Figure 6 ). The metal rimmed cap goes in first. Figure 6 Insert the Pen Body into the Cartridge Holder. The black rod must press against the Rubber Piston on the cartridge. Screw the Pen Body fully onto the Cartridge Holder (See Figure 7 ). Make sure there is no gap between the Pen Body and the Cartridge Holder. The arrow ( ) on the Cartridge Holder should point to the middle of the yellow alignment mark ( ) on the Pen Body. Figure 7 Clean the open end of the Cartridge Holder with an alcohol pad (See Figure 8 ). Figure 8 Pick up a new BD Micro-Fine Pen Needle that is in its Outer Needle Shield. Peel off the protective paper seal (See Figure 9 ). Do not touch the needle. Do not place the open needle on any surface. Use only the BD Micro-Fine 0.33 mm × 12.7 mm (29G) Pen Needles as supplied with the FOLLISTIM AQ Cartridge. Use a new BD Micro-Fine Pen Needle with each injection. Never reuse a needle. Attach a new BD Micro-Fine Pen Needle after you make sure there is a FOLLISTIM AQ Cartridge in the Cartridge Holder. Figure 9 Hold the Outer Needle Shield firmly in one hand while holding the Cartridge Holder firmly in the other hand. Push the end of the Cartridge Holder into the Outer Needle Shield. Screw them tightly together (See Figure 10 ). Place your FOLLISTIM Pen aside. Figure 10 C. Preparing the Injection Site When giving a subcutaneous injection, follow your healthcare provider's instructions about changing the site for each injection. This will help lower your chances of having a skin reaction. Do not inject FOLLISTIM AQ Cartridge into an area that is tender, red, bruised, or hard. The recommended sites for injecting FOLLISTIM AQ Cartridge are: just below your belly button (navel) (See Figure 11 ) Figure 11 the upper outer area of your thigh (See Figure 12 ) Figure 12 Choose an injection site. Clean the skin at the injection site with an alcohol wipe. Clean about two inches around the injection site where the needle will be inserted. Do not touch the cleaned area of skin. D. Dialing the Dose Before You Give the Injection Your healthcare provider will decide on the dose of FOLLISTIM AQ Cartridge to be given. This dose may be increased or decreased as your treatment progresses depending on your individual type of treatment. FOLLISTIM AQ Cartridge using FOLLISTIM Pen can be injected subcutaneously (beneath the skin) in prescribed doses from 50 International Units (IU) up to 450 IU, in marked 25 IU increments. The Dosage Scale on the Pen has numbers and audible clicks to help you set the correct dose. Hold the FOLLISTIM Pen and pull off the outer needle shield. Leave the Inner Needle Shield in place over the needle attached to the Pen (See Figure 13 ). Do not throw away the Outer Needle Shield, you will need it later when you throw away the needle. Figure 13 Carefully remove the Inner Needle Shield and throw it away (discard) (See Figure 14 ). Do not touch the needle or let the needle touch any surface while uncapped. Figure 14 Hold the FOLLISTIM Pen with the needle pointing upwards. Tap the Cartridge Holder gently with your finger to help air bubbles rise to the top of the needle. The small amount of air bubbles will not affect the amount of medicine you receive. With an unused cartridge loaded: Dial the Dosage Knob until you hear 1 click. With the needle pointing upwards, push in the Injection Button. Look for a droplet of medicine at the tip of the needle (See Figure 15 ). If you see the droplet, then you can dial in your dose. If you do not see a droplet, repeat number 1 (above) until you see droplet. You must make sure you see a droplet of medicine ( check the flow of medicine ) or you may not inject the correct dose amount. Figure 15 With a partially used cartridge, to give yourself another dose of medicine you will need to attach a new BD Micro-Fine Pen Needle and look for a droplet forming at the tip of the needle (See Figure 15 ). If you see a droplet, then you can dial in your dose. If no droplet: 1. Dial the Dosage Knob until you hear one click. With the needle pointing upwards, push in the Injection Button. 2. Look for a droplet at the tip of the needle. If you see the droplet, then you can dial in your dose. Your FOLLISTIM AQ Cartridge should be one of the following: Silver Metal Cap – 300 international units Gold Metal Cap – 600 international units Blue Metal Cap – 900 international units If you do not have one of the cartridges above, please contact your healthcare provider. For doses of 50 IU up to 450 IU, turn the Dosage Knob until the correct dosage aligns with the dosage markers on each side of the Dosage Window (See Figure 16 ). Figure 16 If by mistake you dial past the correct dose number, do not try to turn the Dosage Knob backward to fix the mistake. Continue to turn the Dosage Knob in the same direction past the 450 IU mark, as far as it will turn. The Dosage Scale must move freely. Push the Injection Button in all the way (See Figure 17 ). Start to dial again starting from \"0\" upwards. By following these directions, you will not lose any medicine from the FOLLISTIM AQ Cartridge (See \" Checking the Medicine Level Remaining \"). Figure 17 If you turn the Dosage Knob backward to correct the mistake, it will not damage the FOLLISTIM Pen, but you will lose some medicine from the FOLLISTIM AQ Cartridge. Never dial your dose or try to correct a dialing mistake when the needle is still in your skin. You may receive an incorrect dose. If your prescribed dose is more than the deliverable dose of FOLLISTIM Pen or more than the amount remaining in the cartridge, you will need to give yourself more than 1 injection. E. Giving Yourself an Injection Pinch a fold of skin at the cleaned injection site with one hand. Do not touch the cleaned area of skin. With the other hand hold the FOLLISTIM Pen with FOLLISTIM AQ Cartridge loaded and BD Micro-Fine Needle. Use a quick “dart-like” motion to insert the needle straight up and down (90° angle). Press the injection button all the way in to make sure you give yourself a full injection (See Figure 18 ). Wait for 5 seconds before pulling the needle out of the skin. The middle of the Dosage Window should display a dot next to the \"0\". Figure 18 If the injection button does not push in all the way, and the number in the Dosage Window does not read \"0\", it means there is not enough medicine left in the cartridge to complete your prescribed dose. The number in the Dosage Window will give you the amount of medicine needed to complete your dose. Write this number down. This will be the number you dial for the completion of your dose. Start over with a new FOLLISTIM AQ Cartridge and a new needle and follow all the instructions up to this step (See “ Giving Yourself an Injection ”). Make sure you choose a different injection site to complete your prescribed dose of medicine FOLLISTIM AQ Cartridge. Remove the BD Micro-Fine Needle from your skin and firmly press down on the injection site with an alcohol swab. Be very careful when handling the needle. If you are giving an injection to another person, accidental needle sticks with used needles can cause serious infections or infections that may lead to death. Carefully follow these instructions. Place the Outer Needle Shield on a flat table surface with the opening pointing up. The opening of the Outer Needle Shield is the wider end with the rim. Without holding on to the Outer Needle Shield, carefully insert the needle (attached to the FOLLISTIM Pen) straight into the center of the opening of the Outer Needle Shield and push down firmly (See Figure 19 ). Be sure the Outer Needle Shield is completely covering the entire needle. Figure 19 Grip the Outer Needle Shield carefully and use it to unscrew the needle from the Cartridge Holder (See Figure 20 ). Figure 20 Throw away the Outer Needle Shield with the used needle right away. Do not throw away in a trash can. (See \" How Do I Throw Away Used Cartridges and Needles ?\") If there is medicine left in the FOLLISTIM AQ Cartridge for more injections, put the Pen Cap back on the Pen Body and store your FOLLISTIM Pen in a safe place in the refrigerator (not in the freezer) or at room temperature. Never store the FOLLISTIM Pen with a needle attached to it. Unscrew the Pen Body from the Cartridge Holder with the empty FOLLISTIM AQ Cartridge (See Figure 21 ). Figure 21 Remove the empty FOLLISTIM AQ Cartridge from the Cartridge Holder (See Figure 22 ). Safely, throw away (dispose of) the empty FOLLISTIM AQ Cartridge right away. Do not put the cartridge in your household trash. (See \" How Do I Throw Away Used Cartridges and Needles ?\") Figure 22 F. Checking the Medicine Level Remaining For women and men: Have your healthcare provider advise you of the number of prescribed doses that are in the full unused FOLLISTIM AQ Cartridge. Do not use the cartridge beyond the advised number of doses. Otherwise, there may not be enough medicine for your prescribed dose. For women only: Keep a FOLLISTIM Pen Treatment Diary as follows: 1. Record the FOLLISTIM AQ Cartridge content on Day 1. This will either be 300, 600 or 900 international units depending on what your healthcare provider has prescribed for you. 2. Record the dose you have been prescribed for your injection. 3. Subtract your Day 1 dose from the FOLLISTIM AQ Cartridge content (300, 600 or 900 international units). (See Figure 23 .) This will give you the remaining FOLLISTIM AQ Cartridge content after the Day 1 dose is taken. 4. Place the number determined as the content after Day 1 (See number 3 ) in the box as the FOLLISTIM AQ Cartridge content available for Day 2. (See Figure 23 .) 5. Subtract your Day 2 dose from the FOLLISTIM AQ Cartridge content you recorded in Step 4. This will give you the remaining FOLLISTIM AQ Cartridge content after Day 2. Record this number of units. (See Figure 23 .) 6. Repeat the steps to determine the FOLLISTIM AQ Cartridge content available and FOLLISTIM AQ Cartridge remaining for each day of use. Figure 23. Example of Treatment Diary Starting with a 600 International Unit Cartridge If you do not know if there is not enough medicine left in the FOLLISTIM AQ Cartridge for your next prescribed dose, see section \" If There is Not Enough FOLLISTIM AQ in the Cartridge \". G. If There is Not Enough FOLLISTIM AQ in the Cartridge 1. If you realize before you inject that you do not have enough medicine remaining in your FOLLISTIM AQ Cartridge for your complete dose, follow either Option 1 or Option 2. Do not follow both. Option 1: Dial your dose and inject the remaining medicine in the FOLLISTIM AQ Cartridge. The Dosage Knob Injection Button will not push in all the way (do not try to force down the button) and the Dosage Window number will not read \"0\" but will read the number of units you will need to complete your prescribed dose. Write down the number of units needed to complete your dose. Remove the needle and throw it away (dispose of it) properly (see \" How Do I Throw Away Used Cartridges and Needles ?\"). Using the Dosage Knob, reset the Dial Window to \"0\" by turning the Dosage Knob past the 450 IU mark as far as it will turn and push the Injection Button in all the way. Before you replace a FOLLISTIM AQ Cartridge, be sure that a BD Micro-Fine Pen Needle is not attached to the FOLLISTIM Pen. Insert a new cartridge into the FOLLISTIM Pen and attach a new BD Micro-Fine needle. Dial to the number of units you have written down to complete your prescribed dose. Prepare a different injection site and inject the remaining medicine to complete your dose (See \" Giving Yourself an Injection \"). Option 2: Remove the FOLLISTIM AQ Cartridge. Start over with a new FOLLISTIM AQ Cartridge and Insert into the FOLLISTIM Pen. Follow the instructions for \"Dialing the Dose\" and \"Giving Yourself an Injection.\" 2. If you realize after you have inserted the needle at the injection site that you do not have enough medicine remaining in your FOLLISTIM AQ Cartridge for your complete dose: Inject the remaining content in the FOLLISTIM AQ Cartridge. The Injection Button will not push in all the way and the number in the Dosage Window will not read \"0\" but will read the number of units you will need to complete your prescribed dose. Wait 5 seconds before removing the needle from your skin and gently apply pressure to the injection site with an alcohol pad. Throw away (dispose of) the used needle (See \" How Do I Throw Away Used Cartridges and Needles ?\"). Write down the number of units needed to complete your dose. Using the Dosage Knob, reset the Dial Window to \"0\" by turning the Dosage Knob past the 450 IU mark as far as it will turn and push the Injection Button in all the way. Insert a new cartridge into the FOLLISTIM Pen and attach a new BD Micro-Fine needle. Dial to the number you have recorded to complete your prescribed dose. Prepare a different injection site and inject the remaining medicine to complete your dose (See \" Giving Yourself an Injection \"). H. How to Solve Problems with FOLLISTIM AQ Cartridge and FOLLISTIM Pen If you have problems with using the FOLLISTIM AQ Cartridge and the FOLLISTIM Pen, see the following chart . If you still have problems after following the chart or if your problem is not on the chart, contact your healthcare provider. PROBLEM POSSIBLE CAUSES WHAT TO DO The Pen Body will not screw tightly into the Cartridge Holder. Is something in the way? Take out the FOLLISTIM Cartridge and check the Cartridge Holder to see if anything is in the way. Follow the instructions in this pamphlet to Screw the Pen Body fully onto the Cartridge Holder. No medicine is coming out while checking the flow. The Cartridge Holder and the Pen Body are not properly screwed together. Remove the current needle. Carefully follow instructions ( Fig. 19 and Fig. 20 ) to prevent accidental needle sticks. Tighten the Pen Body to the Cartridge Holder ensuring the arrow on the Cartridge Holder is pointing to the middle of the yellow alignment mark on the Pen Body. Attach a new needle to the Pen. Recheck the flow as follows: Dial the Dosage Knob until you hear one click. With needle pointing upwards, push in the Injection Button. Look for a droplet at the tip of the needle. Is the FOLLISTIM Cartridge empty? Change to a new cartridge. Has the needle been properly attached to the FOLLISTIM Pen? Remove needle and replace with a new one, ensuring that the needle is screwed on tightly to the Pen. Recheck the flow as follows: Dial the Dosage Knob until you hear one click. With needle pointing upwards, push in the Injection Button. Look for a droplet at the tip of the needle. You are concerned that you can turn the Dosage Knob to the next number without clicking and the Injection Button spins freely. This is not a problem. The system is in the reset mode. The Injection Button and Dosage Knob must be pushed all the way down to '0' to re-engage the mechanism and the correct dose can now be set. A click will be heard for each setting in the viewing window. The Dosage Knob does not go back to '0' while you are injecting. Is the FOLLISTIM Cartridge empty? Change to a new cartridge. Is the needle blocked? Remove the needle from the skin and dispose of safely. Check the Dosage Window and note how much remaining medicine to inject. Attach a new needle. Recheck the flow as follows: Dial the Dosage Knob until you hear one click. With needle pointing upwards, push in the Injection Button. Look for a droplet at the tip of the needle. Dial remaining dose. Some of the medicine is dripping out of the needle when you withdraw it from your skin. Did you take the needle out of your skin before waiting 5 seconds as directed in Step 15? If this happens you should inform your doctor. To avoid this problem again, you should always wait 5 seconds after you push the Injection Button before you withdraw the needle from your skin. The needle is left on the FOLLISTIM Pen. Have you missed any of the instructions? Dispose of the needle in a properly secured container as instructed by your doctor. Carefully follow instructions ( Fig. 19 and Fig. 20 ) to prevent accidental needle sticks. Change to a new FOLLISTIM Cartridge and a new needle. After your last injection, a remaining volume may be left in the cartridge in addition to the normal quantity of medicine dispensed. The cartridge contains extra volume for checking the medicine flow. This is not a problem. You cannot get the cartridge out of the FOLLISTIM Pen. Is the needle attached? Remove the needle from the FOLLISTIM Pen and dispose of properly. (Unscrew the Cartridge Holder from the Pen Body and take out the cartridge.) You are not sure how much medicine is left in the cartridge, and you do not want to start an injection and then find out that there is not enough medicine. Have you kept good records of your doses? In case of any doubt, you should load a new, unused FOLLISTIM Cartridge into the FOLLISTIM Pen. See \" If There is Not Enough FOLLISTIM AQ in the Cartridge .\" To avoid this problem again, you should record your injections. (Women should use a treatment diary.) Important: If you have a question, always mention the Lot number of your FOLLISTIM Pen as printed on the Pen Body. If you have a complaint, please do not discard any product or packaging. For questions on information contained in this leaflet, call 1-844-674-3200. www.follistim.com How Do I Throw Away Used Cartridges and Needles? Put your used cartridges and needles in an FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and cartridges in your household trash. If you do not have an FDA-cleared sharps container, you may use a household container that is: made of heavy-duty plastic, can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, upright and stable during use, leak resistant, and properly labeled to warn of hazardous waste inside the container. When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used cartridges and needles. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal . Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container. How Do I Care for the FOLLISTIM Pen? 1. Clean all exposed parts of the FOLLISTIM Pen with a clean, damp cloth such as a paper towel. Never wash it in water, detergent, or strong medical cleaners. 2. Handle the FOLLISTIM Pen carefully to avoid causing damage. You could damage the FOLLISTIM Pen by dropping it or handling it roughly. 3. Keep the FOLLISTIM Pen away from dust and dirt. 4. Never store the FOLLISTIM Pen with a needle attached to it. If you store the FOLLISTIM Pen with the needle attached, the medicine could leak out and there is risk of contamination. 5. If the FOLLISTIM Pen breaks or is damaged, do not try to fix it yourself. Contact your healthcare provider. 6. Do not share your FOLLISTIM Pen with another person. Keep FOLLISTIM Pen, FOLLISTIM AQ Cartridge, any other supplies and all medicines out of the reach of children. Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Triangle Rectangle Figure 7 Figure 8 Figure 9 Figure 10 Figure 11 Figure 12 Figure 13 Figure 14 Figure 15 Figure 16 Figure 17 Figure 18 Figure 19 Figure 20 Figure 21 Figure 22 Figure 23","Manufactured by: Organon USA LLC, a subsidiary of ORGANON & Co., Jersey City, NJ 07302, USA U.S. License No. 2331 BD, BD Logo, and BD Micro-Fine are trademarks of Becton, Dickinson and Company. For patent information: www.organon.com/our-solutions/patent/ © 2024 Organon group of companies. All rights reserved. This Instructions for Use was approved by the U.S. Food and Drug Administration Revised: February 2024 usppi-og8328-SOi-2602r002"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION See Dose Conversion Table 1 for FOLLISTIM AQ Cartridge with Pen Injector ( 2.1 ) In Anovulatory Women Undergoing Ovulation Induction ( 2.2 ): Starting daily dose of 50 international units of FOLLISTIM AQ Cartridge is administered subcutaneously for at least the first 7 days. The dose is increased by 25 or 50 international units at weekly intervals until follicular growth and/or serum estradiol levels indicate an adequate response. When an acceptable pre-ovulatory state is achieved, final oocyte maturation is achieved with 5,000 to 10,000 international units of urinary human chorionic gonadotropin (hCG). The woman and her partner should have intercourse daily, beginning on the day prior to the administration of hCG and until ovulation becomes apparent. In Normal Ovulatory Women Undergoing Controlled Ovarian Stimulation as Part of an In Vitro Fertilization or Intracytoplasmic Sperm Injection Cycle ( 2.3 ): Starting dose of 200 international units (actual cartridge doses) of FOLLISTIM AQ Cartridge is administered subcutaneously for at least the first 7 days of treatment. Subsequent doses can be adjusted down or up based upon ovarian response as determined by ultrasound evaluation of follicular growth and serum estradiol levels. Dosage reduction in high responders can be considered from the 6th day of treatment onward according to individual response. Final oocyte maturation is induced with a dose of 5,000-10,000 international units of urinary hCG. Oocyte (egg) retrieval is performed 34 to 36 hours later. Induction of Spermatogenesis in Men ( 2.4 ): Pretreatment with urinary hCG alone (1,500 international units twice weekly) is required. If serum testosterone levels have not normalized after 8 weeks of hCG treatment, the dose may be increased to 3,000 international units twice a week. After normalization of serum testosterone levels, administer 450 international units per week (225 international units twice weekly or 150 international units three times weekly) of FOLLISTIM AQ Cartridge subcutaneously with the same pre-treatment hCG dose used to normalize testosterone levels. 2.1 General Dosing Information Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If the solution is not clear and colorless or has particles in it, the solution should not be used. Do not add any other medicines into the FOLLISTIM AQ Cartridge. FOLLISTIM AQ Cartridge with the pen injector device delivers on average an 18% higher amount of follitropin beta when compared to reconstituted FOLLISTIM delivered with a conventional syringe and needle. When administering FOLLISTIM AQ Cartridge, a lower starting dose and lower dose adjustments (as compared to reconstituted FOLLISTIM) should be considered. For that purpose the following Dose Conversion Table is provided: Table 1: FOLLISTIM AQ Cartridge Administered Subcutaneously with the FOLLISTIM Pen Dose Conversion Table Each value represents an 18% difference rounded to the nearest 25 IU increment. Lyophilized recombinant FSH dosing with ampules or vials, using conventional syringe FOLLISTIM AQ Cartridge dosing with the FOLLISTIM Pen 75 IU 50 IU 150 IU 125 IU 225 IU 175 IU 300 IU 250 IU 375 IU 300 IU 450 IU 375 IU 2.2 Recommended Dosing in Anovulatory Women Undergoing Ovulation Induction The dosing scheme is stepwise and is individualized for each woman [see Clinical Studies (14.1) ] . A starting daily dose of 50 international units of FOLLISTIM AQ Cartridge is administered [see Dosage and Administration (2.1) ] subcutaneously daily for at least the first 7 days. Subsequent dosage adjustments are made at weekly intervals based upon ovarian response. If an increase in dose is indicated by the ovarian response, the increase should be made by 25 or 50 international units of FOLLISTIM AQ Cartridge at weekly intervals until follicular growth and/or serum estradiol levels indicate an adequate ovarian response. The following should be considered when planning the woman's individualized dose: Appropriate FOLLISTIM AQ Cartridge dose adjustment(s) should be used to prevent multiple follicular growth and cycle cancellation. The maximum, individualized, daily dose of FOLLISTIM AQ Cartridge is 250 international units. Treatment should continue until ultrasonic visualizations and/or serum estradiol determinations approximate the pre-ovulatory conditions seen in normal individuals. When pre-ovulatory conditions are reached, 5,000 to 10,000 international units of urinary hCG are used to induce final oocyte maturation and ovulation. The administration of hCG must be withheld in cases where the ovarian monitoring suggests an increased risk of OHSS on the last day of FOLLISTIM AQ Cartridge therapy [see Warnings and Precautions (5.1 , 5.2 , 5.10) ] . The woman and her partner should be encouraged to have intercourse daily, beginning on the day prior to the administration of hCG and until ovulation becomes apparent [see Warnings and Precautions (5.10) ] . During treatment with FOLLISTIM AQ Cartridge and during a two-week post-treatment period, the woman should be assessed at least every other day for signs of excessive ovarian stimulation. It is recommended that FOLLISTIM AQ Cartridge administration be stopped if the ovarian monitoring suggests an increased risk of OHSS or abdominal pain occurs. Most OHSS occurs after treatment has been discontinued and reaches its maximum at about seven to ten days post-ovulation. 2.3 Recommended Dosing in Normal Ovulatory Women Undergoing Controlled Ovarian Stimulation as Part of an In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI) Cycle The dosing scheme follows a stepwise approach and is individualized for each woman. A starting dose of 200 international units (actual cartridge doses) of FOLLISTIM AQ Cartridge is administered [see Dosage and Administration (2.1) ] subcutaneously daily for at least the first 7 days of treatment. Subsequent to the first 7 days of treatment, the dose can be adjusted down or up based upon the woman's ovarian response as determined by ultrasound evaluation of follicular growth and serum estradiol levels. Dosage reduction in high responders can be considered from the 6th day of treatment onward according to individual response. The following should be considered when planning the woman's individualized dose: For most normal responding women, the daily starting dose can be continued until pre-ovulatory conditions are achieved (seven to twelve days). For low or poor responding women, the daily dose should be increased according to the ovarian response. The maximum, individualized, daily dose of FOLLISTIM AQ Cartridge is 500 international units. For high responding women [those at particular risk of abnormal ovarian enlargement and/or ovarian hyperstimulation syndrome (OHSS)], decrease or temporarily stop the daily dose, or discontinue the cycle according to individual response [see Warnings and Precautions (5.1 , 5.2 , 5.10) ] . When a sufficient number of follicles of adequate size are present, dosing of FOLLISTIM AQ Cartridge is stopped and final maturation of the oocytes is induced by administering urinary hCG at a dose of 5,000 to 10,000 international units. The administration of hCG should be withheld in cases where the ovarian monitoring suggests an increased risk of OHSS on the last day of FOLLISTIM AQ Cartridge therapy [see Warnings and Precautions (5.1 , 5.2 , 5.10) ] . Oocyte (egg) retrieval should be performed 34 to 36 hours following the administration of hCG. 2.4 Recommended Dosing for Induction of Spermatogenesis in Men Pretreatment with hCG is required prior to concomitant therapy with FOLLISTIM AQ Cartridge and hCG. An initial dosage of 1,500 international units of urinary hCG should be administered at twice weekly intervals to normalize serum testosterone levels. If serum testosterone levels have not normalized after 8 weeks of hCG treatment, the urinary hCG dose can be increased to 3,000 international units twice weekly [see Clinical Studies (14.3) ] . After normal serum testosterone levels have been reached, FOLLISTIM AQ Cartridge should be administered by subcutaneous injection concomitantly with hCG treatment. FOLLISTIM is given at a dosage of 450 international units per week, as either 225 international units twice weekly or 150 international units three times per week, in combination with the same hCG dose used to normalize testosterone levels. Based on delivery of a higher dose of follitropin beta with the FOLLISTIM AQ Cartridge and pen injector [see Dosage and Administration (2.1) ], a lower dose of FOLLISTIM AQ Cartridge may be considered. The concomitant therapy should be continued for at least 3 to 4 months before any improvement in spermatogenesis can be expected. If a man has not responded after this period, the combination therapy may be continued. Treatment response has been noted at up to 12 months."],"spl_product_data_elements":["Follistim AQ follitropin follitropin follitropin benzyl alcohol methionine polysorbate 20 trisodium citrate dihydrate sucrose water hydrochloric acid sodium hydroxide Follistim AQ follitropin follitropin follitropin benzyl alcohol methionine polysorbate 20 trisodium citrate dihydrate sucrose water hydrochloric acid sodium hydroxide Follistim AQ follitropin follitropin follitropin benzyl alcohol methionine polysorbate 20 trisodium citrate dihydrate sucrose water hydrochloric acid sodium hydroxide"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS FOLLISTIM AQ Cartridge is a clear and colorless solution available as: Injection: 300 international units per 0.36 mL in a single-patient-use cartridge Injection: 600 international units per 0.72 mL in a single-patient-use cartridge Injection: 900 international units per 1.08 mL in a single-patient-use cartridge Injection: FOLLISTIM AQ Cartridge 300 International Units per 0.36 mL in a single-patient-use cartridge ( 3 ) Injection: FOLLISTIM AQ Cartridge 600 International Units per 0.72 mL in a single-patient-use cartridge ( 3 ) Injection: FOLLISTIM AQ Cartridge 900 International Units per 1.08 mL in a single-patient-use cartridge ( 3 )"],"spl_patient_package_insert":["This Patient Information has been approved by the U.S. Food and Drug Administration Revised: February 2026 PATIENT INFORMATION FOLLISTIM ® (Fol-lis-tim) AQ Cartridge (follitropin beta) injection, for subcutaneous use Read this Patient Information before you start using FOLLISTIM ® AQ Cartridge and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment. What is FOLLISTIM AQ Cartridge? FOLLISTIM AQ Cartridge is a prescription medicine that contains follicle-stimulating hormone (FSH). The medicine is taken with the FOLLISTIM Pen. FOLLISTIM AQ Cartridge is used: In women: to help healthy ovaries to develop (mature) and release eggs as part of Assisted Reproductive Treatment programs that use special techniques (skills) to help women get pregnant by causing their ovaries to produce more mature eggs In men: to help produce and develop mature sperm FOLLISTIM AQ Cartridge is not for use in children. Do not use FOLLISTIM AQ Cartridge if you are a woman or man who: is allergic to recombinant human FSH products or any of the ingredients in FOLLISTIM AQ Cartridge. See the end of this leaflet for a complete list of ingredients in FOLLISTIM AQ Cartridge. has a high level of FSH in your blood that show your ovaries (women only) or testes (men only) may be permanently damaged and do not work at all. has uncontrolled thyroid, adrenal, or pituitary problems. is allergic to streptomycin or neomycin which are antibiotics that may be found in small amounts in FOLLISTIM AQ Cartridge. has a tumor in your sex organs (uterus, ovaries, breasts, testes). has a tumor in your brain (hypothalamus), or in your pituitary gland. Do not use FOLLISTIM AQ Cartridge if you are a woman that: is pregnant or thinks they may be pregnant. has abnormal bleeding from your uterus or vagina from an unknown cause. has or have had ovarian cysts or large ovaries from an unknown cause. Before using FOLLISTIM AQ Cartridge, tell your healthcare provider about all of your medical conditions, including if you: have an increased risk of blood clots (thrombosis). have ever had a blood clot (thrombosis), or anyone in your immediate family has ever had a blood clot (thrombosis). had stomach (abdominal) surgery. had twisting of your ovary (ovarian torsion). have polycystic ovary disease. are pregnant or think you may be pregnant. Your healthcare provider will give you a pregnancy test before you start using FOLLISTIM AQ Cartridge. FOLLISTIM AQ Cartridge is not for pregnant women. are breastfeeding or plan to breastfeed. It is not known if the medicine in FOLLISTIM AQ Cartridge passes into your breast milk. You and your healthcare provider should decide if you will take FOLLISTIM AQ Cartridge or breastfeed. Tell your healthcare provider about all the medicines you take , including prescription and non-prescription medicines, vitamins, and herbal supplements. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine. How should I use FOLLISTIM AQ Cartridge? Read the Instructions for Use that comes with FOLLISTIM AQ Cartridge about the right way to use FOLLISTIM AQ Cartridge. Use FOLLISTIM AQ Cartridge exactly as your healthcare provider tells you to. FOLLISTIM AQ Cartridge is injected subcutaneously (beneath the skin) only. Your healthcare provider will tell you how much FOLLISTIM AQ Cartridge to use, how to inject it, and how often it should be injected. Use FOLLISTIM AQ Cartridge only with the FOLLISTIM Pen. FOLLISTIM Pen is not recommended for use if you are blind or visually impaired without the help of a person trained to use the pen. Do not inject FOLLISTIM AQ Cartridge at home until your healthcare provider has taught you the right way to put the FOLLISTIM AQ Cartridge and FOLLISTIM Pen device together and to inject yourself. Do not add any other medicines into the FOLLISTIM AQ Cartridge. Do not change your dose of FOLLISTIM AQ Cartridge unless your healthcare provider tells you to. Call your healthcare provider immediately if you use too much FOLLISTIM AQ Cartridge. If you miss or forget to take a dose, do not double your next dose. Ask your healthcare provider for instructions. Do not re-use the Pen Needle. Your healthcare provider will do blood and urine hormone tests while you are using FOLLISTIM AQ Cartridge. Make sure you follow-up with your healthcare provider to have your blood and urine tested when told to do so. Women: Your healthcare provider may do ultrasound scans of your ovaries. Make sure you follow-up with your healthcare provider to have your ultrasound scans. Men: Your healthcare provider may test your semen while you are using FOLLISTIM AQ Cartridge. Make sure you follow-up with your healthcare provider to give a semen sample for testing. What are the possible side effects of FOLLISTIM AQ Cartridge? FOLLISTIM AQ Cartridge may cause serious side effects in women, including: Ovarian enlargement. FOLLISTIM AQ may cause your ovaries to be abnormally large. Symptoms of large ovaries include bloating or pain in your lower stomach (pelvic) area. Ovarian hyperstimulation syndrome (OHSS). OHSS is a serious side effect that can happen when the ovaries produce too many eggs (overstimulated). In rare cases it has caused death. OHSS causes fluid to build up suddenly in your stomach and chest areas and can cause blood clots to form. OHSS may also happen after you stop using FOLLISTIM AQ Cartridge. Stop using FOLLISTIM AQ Cartridge and call your healthcare provider right away if you have symptoms of OHSS, including: severe lower stomach (pelvic) area pain nausea vomiting weight gain stomach (abdomen) pain bloating diarrhea trouble breathing decreased urine output Lung problems. FOLLISTIM AQ Cartridge may cause you to have fluid in your lungs (atelectasis) and trouble breathing (acute respiratory distress syndrome). Blood clots. FOLLISTIM AQ Cartridge may increase your chance of having blood clots in your blood vessels. Blood clots can cause: blood vessel problems (thrombophlebitis) stroke loss of your arm or leg blood clot in your lungs (pulmonary embolus) heart attack Ovarian torsion. FOLLISTIM AQ Cartridge may increase the chance of twisting of the ovaries in women with certain conditions such as OHSS, pregnancy and previous abdominal surgery. Twisting of the ovary could cause the blood flow to the ovary to be cut off. Pregnancy and birth of multiple babies. Having a pregnancy with more than one baby at a time increases the health risk for you and your babies. Discuss your chances of multiple births with your healthcare provider. Birth defects. A woman’s age, certain sperm problems, genetic background of both parents and a pregnancy with multiple babies can increase the chance that your baby might have birth defects. Ectopic pregnancy (pregnancy outside of the womb). The chance of a pregnancy outside of the womb is increased in women with damaged fallopian tubes. Miscarriage. The chance of loss of an early pregnancy may be increased in women who have difficulty with becoming pregnant at all. Tumors of the ovary. There have been infrequent reports of ovarian tumors in women who have had multiple ovarian stimulation treatments, however there is no confirmed direct link with FOLLISTIM AQ Cartridge. The most common side effects of FOLLISTIM AQ Cartridge include: In women: cyst (closed sac) in the ovary stomach discomfort or pain discomfort or pain in the lower stomach (pelvic) area headache nausea feeling tired In men: headache acne pain at the injection site bruising, swelling or redness at the injection site breast enlargement rash testicular dermoid cyst (closed sac under the skin) Tell your healthcare provider if you have any side effects that bothers you or that does not go away. These are not all the possible side effects of FOLLISTIM AQ Cartridge. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store FOLLISTIM AQ Cartridge? Store unused FOLLISTIM AQ Cartridge in the refrigerator between 36°F to 46°F (2°C to 8°C) until the expiration date, or at room temperature up to 77°F (25°C) for 3 months or until the expiration date, whichever comes first. After first use store FOLLISTIM AQ Cartridge either in the refrigerator or at room temperature between 36°F to 77°F (2°C to 25°C) and throw away (discard) after 28 days. Keep FOLLISTIM AQ Cartridge in the original carton to protect from light. Do not freeze. Keep FOLLISTIM AQ Cartridge and all medicines out of the reach of children. General information about the safe and effective use of FOLLISTIM AQ Cartridge. Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet. Do not use FOLLISTIM AQ Cartridge for a condition for which it was not prescribed. Do not give FOLLISTIM AQ Cartridge to other people, even if they have the same condition that you have. It may harm them. You can ask your pharmacist or healthcare provider for more information about FOLLISTIM AQ Cartridge that is written for healthcare professionals. What are the ingredients in FOLLISTIM AQ Cartridge? Active ingredient: follitropin beta Inactive ingredients: benzyl alcohol, methionine, polysorbate 20, sodium citrate, sucrose, Water for Injection USP. Hydrochloric acid NF and/or sodium hydroxide NF are used to adjust the pH. Manufactured by: Organon USA LLC, a subsidiary of ORGANON & Co., Jersey City, NJ 07302, USA U.S. License No. 2331 BD, BD Logo and BD Micro-Fine are trademarks of Becton, Dickinson and Company. For patent information: www.organon.com/our-solutions/patent/ © 2026 Organon group of companies. All rights reserved. For more information, go to www.follistim.com or call 1-844-674-3200. usppi-og8328-SOi-2602r002"],"clinical_pharmacology_table":["
Table 5: Mean (SD) Pharmacokinetic Parameters of a Single Subcutaneous Injection of 150 IU of FOLLISTIM AQ Cartridge (n=20)
AUC0–∞ (IU/L*h)Cmax (IU/L)tmax (h)t½ (h)CLapp (L/h/kg)
AUC0–∞ Area under the curve Cmax Maximum concentration tmax Time to maximum concentration t½ Elimination half-life CLapp Clearance
FOLLISTIM AQ215.13.412.933.40.01
Cartridge(45.8)(0.7)(6.2)(4.2)(0.003)
","
Figure 1: Mean (SD) Serum Trough Concentrations of FSH in Men Following Subcutaneous Administration of FOLLISTIM Using Two Different Dosing Schedules (150 International Units Three Times a Week or 225 International Units Twice a Week)
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: It is not known whether this drug is excreted in human milk. ( 8.2 ) 8.1 Pregnancy Risk Summary FOLLISTIM AQ Cartridge is contraindicated for use in pregnant women. The incidence of congenital malformations after some Assisted Reproductive Technology, specifically in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)], may be slightly higher than that after spontaneous conception. This slightly higher incidence is thought to be related to differences in parental characteristics (e.g., maternal age, maternal and paternal genetic background, sperm characteristics) and to a higher incidence of multi-fetal gestations after IVF or ICSI [see Warnings and Precautions (5.6) ] . There is no human data that the use of gonadotropins (including FOLLISTIM AQ Cartridge) alone or as part of IVF or ICSI cycles, increases the risk of congenital malformations. The risk of spontaneous abortion (miscarriage) is increased in women who have used gonadotropins products to achieve pregnancy [see Warnings and Precautions (5.8) ] . In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. 8.2 Lactation Risk Summary It is not known whether this drug is excreted in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for FOLLISTIM AQ Cartridge and any potential adverse effects on the breastfed child from FOLLISTIM AQ Cartridge or from the underlying maternal condition. 8.4 Pediatric Use FOLLISTIM AQ Cartridge is not indicated for use in pediatric patients. Clinical studies have not been conducted in the pediatric population. 8.5 Geriatric Use Clinical studies of FOLLISTIM AQ Cartridge have not been conducted in patients 65 years of age and older."],"spl_unclassified_section_table":["
INSTRUCTIONS FOR USE FOLLISTIM® (Fol΄-lis-tim) AQ Cartridge (follitropin beta) injection, for subcutaneous use
","
Figure 1. FOLLISTIM Pen and its Parts
","
Figure 2. Parts of FOLLISTIM AQ Cartridge
","
Figure 3. Parts of BD Micro-Fine Pen Needle Unit
","
Figure 4
","
Figure 5
","
Figure 6
","
Figure 7
","
Figure 8
","
Figure 9
","
Figure 10
","
Figure 11
","
Figure 12
","
Figure 13
","
Figure 14
","
Figure 15
","
Figure 16
","
Figure 17
","
Figure 18
","
Figure 19
","
Figure 20
","
Figure 21
","
Figure 22
","
PROBLEMPOSSIBLE CAUSESWHAT TO DO
The Pen Body will not screw tightly into the Cartridge Holder.Is something in the way?Take out the FOLLISTIM Cartridge and check the Cartridge Holder to see if anything is in the way. Follow the instructions in this pamphlet to Screw the Pen Body fully onto the Cartridge Holder.
No medicine is coming out while checking the flow.The Cartridge Holder and the Pen Body are not properly screwed together.Remove the current needle. Carefully follow instructions (Fig. 19 and Fig. 20) to prevent accidental needle sticks. Tighten the Pen Body to the Cartridge Holder ensuring the arrow on the Cartridge Holder is pointing to the middle of the yellow alignment mark on the Pen Body. Attach a new needle to the Pen. Recheck the flow as follows:Dial the Dosage Knob until you hear one click. With needle pointing upwards, push in the Injection Button.Look for a droplet at the tip of the needle.
Is the FOLLISTIM Cartridge empty?Change to a new cartridge.
Has the needle been properly attached to the FOLLISTIM Pen?Remove needle and replace with a new one, ensuring that the needle is screwed on tightly to the Pen. Recheck the flow as follows:Dial the Dosage Knob until you hear one click. With needle pointing upwards, push in the Injection Button.Look for a droplet at the tip of the needle.
You are concerned that you can turn the Dosage Knob to the next number without clicking and the Injection Button spins freely.This is not a problem.The system is in the reset mode. The Injection Button and Dosage Knob must be pushed all the way down to '0' to re-engage the mechanism and the correct dose can now be set. A click will be heard for each setting in the viewing window.
The Dosage Knob does not go back to '0' while you are injecting.Is the FOLLISTIM Cartridge empty?Change to a new cartridge.
Is the needle blocked?Remove the needle from the skin and dispose of safely.Check the Dosage Window and note how much remaining medicine to inject.Attach a new needle. Recheck the flow as follows: Dial the Dosage Knob until you hear one click. With needle pointing upwards, push in the Injection Button.Look for a droplet at the tip of the needle.Dial remaining dose.
Some of the medicine is dripping out of the needle when you withdraw it from your skin.Did you take the needle out of your skin before waiting 5 seconds as directed in Step 15?If this happens you should inform your doctor. To avoid this problem again, you should always wait 5 seconds after you push the Injection Button before you withdraw the needle from your skin.
The needle is left on the FOLLISTIM Pen.Have you missed any of the instructions?Dispose of the needle in a properly secured container as instructed by your doctor. Carefully follow instructions (Fig. 19 and Fig. 20) to prevent accidental needle sticks. Change to a new FOLLISTIM Cartridge and a new needle.
After your last injection, a remaining volume may be left in the cartridge in addition to the normal quantity of medicine dispensed.The cartridge contains extra volume for checking the medicine flow.This is not a problem.
You cannot get the cartridge out of the FOLLISTIM Pen.Is the needle attached?Remove the needle from the FOLLISTIM Pen and dispose of properly. (Unscrew the Cartridge Holder from the Pen Body and take out the cartridge.)
You are not sure how much medicine is left in the cartridge, and you do not want to start an injection and then find out that there is not enough medicine.Have you kept good records of your doses?In case of any doubt, you should load a new, unused FOLLISTIM Cartridge into the FOLLISTIM Pen. See "If There is Not Enough FOLLISTIM AQ in the Cartridge." To avoid this problem again, you should record your injections. (Women should use a treatment diary.)
"],"dosage_and_administration_table":["
Table 1: FOLLISTIM AQ Cartridge Administered Subcutaneously with the FOLLISTIM Pen Dose Conversion Table Each value represents an 18% difference rounded to the nearest 25 IU increment.
Lyophilized recombinant FSH dosing with ampules or vials, using conventional syringeFOLLISTIM AQ Cartridge dosing with the FOLLISTIM Pen
75 IU50 IU
150 IU125 IU
225 IU175 IU
300 IU250 IU
375 IU300 IU
450 IU375 IU
"],"spl_patient_package_insert_table":["
This Patient Information has been approved by the U.S. Food and Drug AdministrationRevised: February 2026
PATIENT INFORMATION FOLLISTIM® (Fol-lis-tim) AQ Cartridge (follitropin beta) injection, for subcutaneous use
Read this Patient Information before you start using FOLLISTIM® AQ Cartridge and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment.
What is FOLLISTIM AQ Cartridge? FOLLISTIM AQ Cartridge is a prescription medicine that contains follicle-stimulating hormone (FSH). The medicine is taken with the FOLLISTIM Pen. FOLLISTIM AQ Cartridge is used: In women:to help healthy ovaries to develop (mature) and release eggsas part of Assisted Reproductive Treatment programs that use special techniques (skills) to help women get pregnant by causing their ovaries to produce more mature eggsIn men:to help produce and develop mature sperm FOLLISTIM AQ Cartridge is not for use in children.
Do not use FOLLISTIM AQ Cartridge if you are a woman or man who:is allergic to recombinant human FSH products or any of the ingredients in FOLLISTIM AQ Cartridge. See the end of this leaflet for a complete list of ingredients in FOLLISTIM AQ Cartridge.has a high level of FSH in your blood that show your ovaries (women only) or testes (men only) may be permanently damaged and do not work at all.has uncontrolled thyroid, adrenal, or pituitary problems.is allergic to streptomycin or neomycin which are antibiotics that may be found in small amounts in FOLLISTIM AQ Cartridge.has a tumor in your sex organs (uterus, ovaries, breasts, testes).has a tumor in your brain (hypothalamus), or in your pituitary gland.Do not use FOLLISTIM AQ Cartridge if you are a woman that:is pregnant or thinks they may be pregnant.has abnormal bleeding from your uterus or vagina from an unknown cause.has or have had ovarian cysts or large ovaries from an unknown cause.
Before using FOLLISTIM AQ Cartridge, tell your healthcare provider about all of your medical conditions, including if you:have an increased risk of blood clots (thrombosis).have ever had a blood clot (thrombosis), or anyone in your immediate family has ever had a blood clot (thrombosis).had stomach (abdominal) surgery.had twisting of your ovary (ovarian torsion).have polycystic ovary disease.are pregnant or think you may be pregnant. Your healthcare provider will give you a pregnancy test before you start using FOLLISTIM AQ Cartridge. FOLLISTIM AQ Cartridge is not for pregnant women.are breastfeeding or plan to breastfeed. It is not known if the medicine in FOLLISTIM AQ Cartridge passes into your breast milk. You and your healthcare provider should decide if you will take FOLLISTIM AQ Cartridge or breastfeed.Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.
How should I use FOLLISTIM AQ Cartridge?Read the Instructions for Use that comes with FOLLISTIM AQ Cartridge about the right way to use FOLLISTIM AQ Cartridge. Use FOLLISTIM AQ Cartridge exactly as your healthcare provider tells you to.FOLLISTIM AQ Cartridge is injected subcutaneously (beneath the skin) only.Your healthcare provider will tell you how much FOLLISTIM AQ Cartridge to use, how to inject it, and how often it should be injected.Use FOLLISTIM AQ Cartridge only with the FOLLISTIM Pen.FOLLISTIM Pen is not recommended for use if you are blind or visually impaired without the help of a person trained to use the pen.Do not inject FOLLISTIM AQ Cartridge at home until your healthcare provider has taught you the right way to put the FOLLISTIM AQ Cartridge and FOLLISTIM Pen device together and to inject yourself.Do not add any other medicines into the FOLLISTIM AQ Cartridge.Do not change your dose of FOLLISTIM AQ Cartridge unless your healthcare provider tells you to.Call your healthcare provider immediately if you use too much FOLLISTIM AQ Cartridge.If you miss or forget to take a dose, do not double your next dose. Ask your healthcare provider for instructions.Do not re-use the Pen Needle.Your healthcare provider will do blood and urine hormone tests while you are using FOLLISTIM AQ Cartridge. Make sure you follow-up with your healthcare provider to have your blood and urine tested when told to do so.Women:Your healthcare provider may do ultrasound scans of your ovaries. Make sure you follow-up with your healthcare provider to have your ultrasound scans.Men: Your healthcare provider may test your semen while you are using FOLLISTIM AQ Cartridge. Make sure you follow-up with your healthcare provider to give a semen sample for testing.
What are the possible side effects of FOLLISTIM AQ Cartridge? FOLLISTIM AQ Cartridge may cause serious side effects in women, including:Ovarian enlargement. FOLLISTIM AQ may cause your ovaries to be abnormally large. Symptoms of large ovaries include bloating or pain in your lower stomach (pelvic) area.Ovarian hyperstimulation syndrome (OHSS). OHSS is a serious side effect that can happen when the ovaries produce too many eggs (overstimulated). In rare cases it has caused death. OHSS causes fluid to build up suddenly in your stomach and chest areas and can cause blood clots to form. OHSS may also happen after you stop using FOLLISTIM AQ Cartridge. Stop using FOLLISTIM AQ Cartridge and call your healthcare provider right away if you have symptoms of OHSS, including:
severe lower stomach (pelvic) area painnauseavomitingweight gainstomach (abdomen) painbloatingdiarrheatrouble breathingdecreased urine output
Lung problems. FOLLISTIM AQ Cartridge may cause you to have fluid in your lungs (atelectasis) and trouble breathing (acute respiratory distress syndrome).Blood clots. FOLLISTIM AQ Cartridge may increase your chance of having blood clots in your blood vessels. Blood clots can cause: blood vessel problems (thrombophlebitis)strokeloss of your arm or legblood clot in your lungs (pulmonary embolus)heart attackOvarian torsion. FOLLISTIM AQ Cartridge may increase the chance of twisting of the ovaries in women with certain conditions such as OHSS, pregnancy and previous abdominal surgery. Twisting of the ovary could cause the blood flow to the ovary to be cut off.Pregnancy and birth of multiple babies. Having a pregnancy with more than one baby at a time increases the health risk for you and your babies. Discuss your chances of multiple births with your healthcare provider.Birth defects. A woman’s age, certain sperm problems, genetic background of both parents and a pregnancy with multiple babies can increase the chance that your baby might have birth defects.Ectopic pregnancy (pregnancy outside of the womb). The chance of a pregnancy outside of the womb is increased in women with damaged fallopian tubes.Miscarriage. The chance of loss of an early pregnancy may be increased in women who have difficulty with becoming pregnant at all.Tumors of the ovary. There have been infrequent reports of ovarian tumors in women who have had multiple ovarian stimulation treatments, however there is no confirmed direct link with FOLLISTIM AQ Cartridge. The most common side effects of FOLLISTIM AQ Cartridge include: In women:cyst (closed sac) in the ovarystomach discomfort or paindiscomfort or pain in the lower stomach (pelvic) areaheadachenauseafeeling tiredIn men:headacheacnepain at the injection sitebruising, swelling or redness at the injection sitebreast enlargement rashtesticular dermoid cyst (closed sac under the skin) Tell your healthcare provider if you have any side effects that bothers you or that does not go away. These are not all the possible side effects of FOLLISTIM AQ Cartridge. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store FOLLISTIM AQ Cartridge?Store unused FOLLISTIM AQ Cartridge in the refrigerator between 36°F to 46°F (2°C to 8°C) until the expiration date, or at room temperature up to 77°F (25°C) for 3 months or until the expiration date, whichever comes first.After first use store FOLLISTIM AQ Cartridge either in the refrigerator or at room temperature between 36°F to 77°F (2°C to 25°C) and throw away (discard) after 28 days.Keep FOLLISTIM AQ Cartridge in the original carton to protect from light.Do not freeze.Keep FOLLISTIM AQ Cartridge and all medicines out of the reach of children.
General information about the safe and effective use of FOLLISTIM AQ Cartridge. Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet. Do not use FOLLISTIM AQ Cartridge for a condition for which it was not prescribed. Do not give FOLLISTIM AQ Cartridge to other people, even if they have the same condition that you have. It may harm them. You can ask your pharmacist or healthcare provider for more information about FOLLISTIM AQ Cartridge that is written for healthcare professionals.
What are the ingredients in FOLLISTIM AQ Cartridge? Active ingredient: follitropin beta Inactive ingredients: benzyl alcohol, methionine, polysorbate 20, sodium citrate, sucrose, Water for Injection USP. Hydrochloric acid NF and/or sodium hydroxide NF are used to adjust the pH. Manufactured by: Organon USA LLC, a subsidiary of ORGANON & Co., Jersey City, NJ 07302, USA U.S. License No. 2331 BD, BD Logo and BD Micro-Fine are trademarks of Becton, Dickinson and Company. For patent information: www.organon.com/our-solutions/patent/ © 2026 Organon group of companies. All rights reserved. For more information, go to www.follistim.com or call 1-844-674-3200. usppi-og8328-SOi-2602r002
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 300 IU Kit Carton NDC 78206-129-01 Rx only Follistim ® AQ Cartridge 300 IU (follitropin beta) injection For use only with Follistim Pen ® , available separately For Subcutaneous Use For Single Patient Use Only Contents: 1 Sterile Prefilled Cartridge containing 0.36 mL Follistim ® 5 BD Micro-Fine™ Pen Needles Dispense with Full Prescribing Information PRINCIPAL DISPLAY PANEL - 300 IU Kit Carton","PRINCIPAL DISPLAY PANEL - 600 IU Kit Carton NDC 78206-130-01 Rx only Follistim ® AQ Cartridge 600 IU (follitropin beta) injection For use only with Follistim Pen ® , available separately For Subcutaneous Use For Single Patient Use Only Contents: 1 Sterile Prefilled Cartridge containing 0.72 mL Follistim ® 7 BD Micro-Fine™ Pen Needles Dispense with Full Prescribing Information PRINCIPAL DISPLAY PANEL - 600 IU Kit Carton","PRINCIPAL DISPLAY PANEL - 900 IU Kit Carton NDC 78206-131-01 Rx only Follistim ® AQ Cartridge 900 IU (follitropin beta) injection For use only with Follistim Pen ® , available separately For Subcutaneous Use For Single Patient Use Only Contents: 1 Sterile Prefilled Cartridge containing 1.08 mL Follistim ® 10 BD Micro-Fine™ Pen Needles Dispense with Full Prescribing Information PRINCIPAL DISPLAY PANEL - 900 IU Kit Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term toxicity studies in animals have not been performed with FOLLISTIM to evaluate the carcinogenic potential of the drug. FOLLISTIM was not mutagenic in the Ames test using S. typhimurium and E. coli tester strains and did not produce chromosomal aberrations in an in vitro assay using human lymphocytes."]},"tags":[{"label":"Gonadotropin","category":"class"},{"label":"Biologic","category":"modality"},{"label":"Follicle-stimulating hormone receptor","category":"target"},{"label":"FSHR","category":"gene"},{"label":"G03GA04","category":"atc"},{"label":"Subcutaneous","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Ovulation induction","category":"indication"},{"label":"Serono","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Hormones","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OVARIAN HYPERSTIMULATION SYNDROME","source":"FDA FAERS","actionTaken":"704 reports"},{"date":"","signal":"ASCITES","source":"FDA FAERS","actionTaken":"224 reports"},{"date":"","signal":"ABDOMINAL DISTENSION","source":"FDA FAERS","actionTaken":"175 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"146 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"144 reports"},{"date":"","signal":"ABORTION SPONTANEOUS","source":"FDA FAERS","actionTaken":"137 reports"},{"date":"","signal":"ABDOMINAL PAIN","source":"FDA FAERS","actionTaken":"133 reports"},{"date":"","signal":"NO ADVERSE EVENT","source":"FDA FAERS","actionTaken":"132 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"109 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"93 reports"}],"commonSideEffects":[{"effect":"Ovarian Hyperstimulation Syndrome","drugRate":"7.6%","severity":"serious","_validated":true},{"effect":"Pelvic discomfort","drugRate":"8.3%","severity":"common","_validated":true},{"effect":"Abdominal discomfort","drugRate":"2.9%","severity":"mild","_validated":true},{"effect":"Abdominal pain","drugRate":"3.0%","severity":"mild","_validated":true},{"effect":"Ovarian cyst","drugRate":"3.0%","severity":"mild","_validated":true},{"effect":"Headache","drugRate":"7.3%","severity":"common","_validated":true},{"effect":"Nausea","drugRate":"3.9%","severity":"mild","_validated":true},{"effect":"Pelvic Pain","drugRate":"5.5%","severity":"common","_validated":true},{"effect":"Fatigue","drugRate":"2.3%","severity":"mild","_validated":true},{"effect":"Injection site reaction","drugRate":"6.7%","severity":"common","_validated":true},{"effect":"Injection site pain","drugRate":"6.7%","severity":"common","_validated":true},{"effect":"Acne","drugRate":"6.7%","severity":"common","_validated":true},{"effect":"Rash","drugRate":"3.3%","severity":"mild","_validated":true},{"effect":"Gynecomastia","drugRate":"3.3%","severity":"mild","_validated":true},{"effect":"Dermoid cyst","drugRate":"3.3%","severity":"mild","_validated":true},{"effect":"Abdominal distension","drugRate":"reported","severity":"unknown"},{"effect":"Constipation","drugRate":"reported","severity":"unknown"},{"effect":"Diarrhea","drugRate":"reported","severity":"unknown"},{"effect":"Breast tenderness","drugRate":"reported","severity":"unknown"},{"effect":"Metrorrhagia","drugRate":"reported","severity":"unknown"},{"effect":"Ovarian enlargement","drugRate":"reported","severity":"unknown"},{"effect":"Vaginal hemorrhage","drugRate":"reported","severity":"unknown"},{"effect":"Thromboembolism","drugRate":"reported","severity":"serious"}],"specialPopulations":{"Pregnancy":"Pregnancy Category X: Follistim AQ Cartridge should not be used during pregnancy. Teratogenic effects. Animal Data: Embryofetal development studies with recombinant human FSH in rats, where dosing occurred during organogenesis, showed dose dependent increase in difficult and prolonged parturition in dams, and dose dependent increases in resorptions, pre- and post-implantation losses, and stillborn pups at doses representing and 41 times the lowest clinical dose of 75 IU based on body surface area.","Geriatric use":"Clinical studies of Follistim did not include subjects aged 65 and over.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established.","Nursing Mothers":"It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in the nursing infant from Follistim AQ Cartridge, decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother."}},"trials":[],"aliases":[],"company":"Serono","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=FOLLITROPIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:07:08.628927+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:07:28.657954+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:07:15.368631+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T01:07:08.706886+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:07:07.737324+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FOLLITROPIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:07:15.750426+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:07:01.933198+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:07:01.933226+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:07:01.933232+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:07:17.316129+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Follicle stimulating hormone receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:07:16.805439+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297955/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:07:16.458423+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"BLA021211","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:07:01.933234+00:00"}},"allNames":"urofollitropin","offLabel":[],"synonyms":["follitropin delta","follitropin alfa","follitropin beta","follitropin alfa/beta","follicle-stimulating hormone","urofollitropin","follitropin","human follicle stimulating hormone","FSH"],"timeline":[{"date":"1986-09-18","type":"positive","source":"DrugCentral","milestone":"FDA approval (Serono)"},{"date":"1996-05-02","type":"positive","source":"DrugCentral","milestone":"EMA approval (N.V. Organon)"},{"date":"2006-01-23","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Serono Japan)"}],"aiSummary":"Follitropin, marketed by Serono, is a well-established ovulation induction therapy that mimics the action of follicle-stimulating hormone to promote follicle growth and ovulation. Its key strength lies in its long-standing market presence and the patent protection extending to 2028, which helps maintain its competitive edge against same-class drugs like chorionic gonadotrophin, lutropin alfa, and choriogonadotropin alfa. The primary risk to Follitropin's market position is the potential for increased competition as some of these same-class drugs have already received FDA approval and may gain further traction.","approvals":[{"date":"1986-09-18","orphan":true,"company":"SERONO","regulator":"FDA"},{"date":"1996-05-02","orphan":false,"company":"N.V. Organon","regulator":"EMA"},{"date":"2006-01-23","orphan":false,"company":"SERONO JAPAN","regulator":"PMDA"}],"brandName":"Urofollitropin","ecosystem":[{"indication":"Ovulation induction","otherDrugs":[{"name":"clomifene","slug":"clomifene","company":"Sanofi Aventis Us"},{"name":"ganirelix","slug":"ganirelix","company":"Organon Usa Inc"}],"globalPrevalence":null}],"mechanism":{"target":"Follicle-stimulating hormone receptor","novelty":"First-in-class","targets":[{"gene":"FSHR","source":"DrugCentral","target":"Follicle-stimulating hormone receptor","protein":"Follicle-stimulating hormone receptor"}],"modality":"Biologic","drugClass":"Gonadotropin [EPC]","explanation":"Women:Follicle-stimulating hormone (FSH), the active component in Follistim AQ Cartridge, is required for normal follicular growth, maturation, and gonadal steroid production.In women, the level of FSH is critical for the onset and duration of follicular development, and consequently for the timing and number of follicles reaching maturity. Follistim AQ Cartridge stimulates ovarian follicular growth in women who do not have primary ovarian failure. In order to effect the final phase of follicle maturation, resumption of meiosis and rupture of the follicle in the absence of an endogenous LH surge, human chorionic gonadotropin (hCG) must be given following treatment with Follistim AQ Cartridge when patient monitoring indicates appropriate follicular development parameters have been reached.. Men:Follistim when administered with hCG stimulates spermatogenesis in men with hypogonadotropic hypogonadism. FSH, the active component of Follistim, is the pituitary hormo","oneSentence":"FOLLITROPIN works by mimicking the action of follicle-stimulating hormone to stimulate follicle growth and ovulation.","technicalDetail":"FOLLITROPIN binds to the follicle-stimulating hormone receptor, activating the G-protein coupled receptor pathway and stimulating the production of cyclic AMP, which in turn activates the downstream signaling pathways involved in follicular growth and ovulation."},"commercial":{"launchDate":"1986","_launchSource":"DrugCentral (FDA 1986-09-18, SERONO)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4928","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FOLLITROPIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FOLLITROPIN","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T11:37:46.608068","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:07:28.660625+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","company":"Organon LLC","brandName":"Follistim AQ","isOriginal":false,"marketingStatus":"BLA"}],"competitors":[{"drugName":"chorionic gonadotrophin","drugSlug":"chorionic-gonadotrophin","fdaApproval":"","relationship":"same-class"},{"drugName":"lutropin alfa","drugSlug":"lutropin-alfa","fdaApproval":"2004-10-08","relationship":"same-class"},{"drugName":"choriogonadotropin alfa","drugSlug":"choriogonadotropin-alfa","fdaApproval":"2000-09-20","relationship":"same-class"}],"genericName":"follitropin","indications":{"approved":[{"name":"Ovulation induction","source":"DrugCentral","snomedId":61285001,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"chorionic-gonadotrophin","brandName":"chorionic gonadotrophin","genericName":"chorionic gonadotrophin","approvalYear":"","relationship":"same-class"},{"drugId":"lutropin-alfa","brandName":"lutropin alfa","genericName":"lutropin alfa","approvalYear":"2004","relationship":"same-class"},{"drugId":"choriogonadotropin-alfa","brandName":"choriogonadotropin alfa","genericName":"choriogonadotropin alfa","approvalYear":"2000","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07269327","phase":"PHASE1","title":"An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2025-11-24","conditions":["Fertility"],"enrollment":24,"completionDate":"2026-03-09"},{"nctId":"NCT07340827","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)","status":"RECRUITING","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2026-02-05","conditions":["Infertility"],"enrollment":333,"completionDate":"2029-06-30"},{"nctId":"NCT07477340","phase":"","title":"Plasma Relaxin Measurement Based on Endometrial Preparation for Embryo Transfer","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-05-01","conditions":["Infertility","Embryos Transfert"],"enrollment":60,"completionDate":"2028-02-01"},{"nctId":"NCT04037254","phase":"PHASE1,PHASE2","title":"Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2019-10-08","conditions":["Prostate Adenocarcinoma","Stage IIC Prostate Cancer AJCC v8","Stage III Prostate Cancer AJCC v8","Stage IIIA Prostate Cancer AJCC v8","Stage IIIB Prostate Cancer AJCC v8","Stage IIIC Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8"],"enrollment":22,"completionDate":"2025-12-23"},{"nctId":"NCT07153367","phase":"PHASE2","title":"Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE)","status":"RECRUITING","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2025-12-17","conditions":["Infertility","Insemination"],"enrollment":80,"completionDate":"2028-03-17"},{"nctId":"NCT07457684","phase":"","title":"Comparison of Follitropin Delta and Follitropin Alfa in Combination With Menotropin","status":"COMPLETED","sponsor":"Clinique Ovo","startDate":"2025-12-05","conditions":["IVF Outcomes","OVARIAN STIMULATION"],"enrollment":846,"completionDate":"2025-12-15"},{"nctId":"NCT06134479","phase":"PHASE3","title":"Comparison of Sequential CFA vs CFA +rFSH for Elective Fertility Preservation.","status":"COMPLETED","sponsor":"Fundación Santiago Dexeus Font","startDate":"2023-12-12","conditions":["Fertility"],"enrollment":194,"completionDate":"2025-09-09"},{"nctId":"NCT07097259","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2025-07-21","conditions":["Hypogonadism"],"enrollment":55,"completionDate":"2025-12-23"},{"nctId":"NCT07423143","phase":"NA","title":"Menopausal Impact of Opportunistic Salpingectomy for Ovarian Cancer Prevention","status":"NOT_YET_RECRUITING","sponsor":"Umeå University","startDate":"2026-03","conditions":["Menopause","Opportunistic Salpingectomy"],"enrollment":2100,"completionDate":"2057-12"},{"nctId":"NCT06864793","phase":"PHASE1","title":"Study on the Pharmacokinetics and Safety of QL1012D and Gonal-F® in Healthy Female Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-04-06","conditions":["Infertility, Female"],"enrollment":48,"completionDate":"2026-04"},{"nctId":"NCT06173869","phase":"PHASE3","title":"A Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in China","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2024-03-29","conditions":["Infertility, Female"],"enrollment":301,"completionDate":"2025-05-31"},{"nctId":"NCT07348757","phase":"","title":"rFSH vs rFSH+rLH in Dydrogesterone-Based Progestin Protocol: A Prospective Study","status":"RECRUITING","sponsor":"Centrum Clinic IVF Center","startDate":"2026-01-05","conditions":["InVitro Fertilization","Gonadotropins"],"enrollment":300,"completionDate":"2026-05-10"},{"nctId":"NCT06440850","phase":"PHASE2","title":"Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-07-15","conditions":["Thyroid Gland Follicular Carcinoma","Thyroid Gland Oncocytic Carcinoma","Thyroid Gland Papillary Carcinoma"],"enrollment":21,"completionDate":"2026-11-22"},{"nctId":"NCT06659692","phase":"PHASE1","title":"Pharmacokinetics of FSH and hCG Following Multiple Dose of Gonadotropins-IBSA.","status":"COMPLETED","sponsor":"IBSA Institut Biochimique SA","startDate":"2024-10-10","conditions":["Ovarian Stimulation","Infertility"],"enrollment":28,"completionDate":"2025-08-29"},{"nctId":"NCT06781957","phase":"PHASE1","title":"Pharmacokinetics of FSH and hCG After a Single Subcutaneous Injection of Gonadotropins-IBSA","status":"COMPLETED","sponsor":"IBSA Institut Biochimique SA","startDate":"2024-09-15","conditions":["OVARIAN STIMULATION","Infertility"],"enrollment":29,"completionDate":"2026-01-13"},{"nctId":"NCT07346235","phase":"PHASE3","title":"150 IU vs. 225 IU FSH in Normal Responders: The OPTIMAL-DOSE Trial","status":"NOT_YET_RECRUITING","sponsor":"American Hospital 2 Kosovo","startDate":"2026-03-01","conditions":["Infertility, Female"],"enrollment":440,"completionDate":"2029-01-15"},{"nctId":"NCT06175832","phase":"PHASE4","title":"PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2025-01-27","conditions":["Ovarian Stimulation","Quality of Life","Preimplantation Genetic Testing","Fertility Preservation"],"enrollment":60,"completionDate":"2027-12-31"},{"nctId":"NCT04746313","phase":"","title":"Prevalence of Hyperprolactinemia in Systemic Scleroderma","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2021-03-01","conditions":["Sclerosis, Systemic","Scleroderma","Hyperprolactinemia"],"enrollment":71,"completionDate":"2021-05-12"},{"nctId":"NCT00854373","phase":"PHASE4","title":"Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2007-06-01","conditions":["Infertility"],"enrollment":232,"completionDate":"2010-04-20"},{"nctId":"NCT00984399","phase":"NA","title":"Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2009-09-22","conditions":["Atrophic Vaginitis","Breast Cancer"],"enrollment":31,"completionDate":"2024-05-13"},{"nctId":"NCT05873725","phase":"","title":"Retrospective Study of High Dose Follitropin Delta in a Mixed Protocol With Human Chorionic Gonadotropin","status":"COMPLETED","sponsor":"Clinique Ovo","startDate":"2023-05-20","conditions":["IVF","Infertility"],"enrollment":118,"completionDate":"2024-03-19"},{"nctId":"NCT05316129","phase":"PHASE1","title":"Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-04-28","conditions":["Ovarian Cancer"],"enrollment":10,"completionDate":"2029-05"},{"nctId":"NCT04166825","phase":"NA","title":"Ovarian Hyperstimulation and Fibrin Clot Properties.","status":"RECRUITING","sponsor":"Jagiellonian University","startDate":"2019-11-18","conditions":["Fibrin Blood Clot","Infertility, Female","Endometriosis"],"enrollment":300,"completionDate":"2026-01"},{"nctId":"NCT02892942","phase":"PHASE4","title":"NATural Ovarian Stimulation","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-01-13","conditions":["Infertility"],"enrollment":129,"completionDate":"2019-02-08"},{"nctId":"NCT06466486","phase":"PHASE1","title":"An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation","status":"TERMINATED","sponsor":"Ferring Pharmaceuticals","startDate":"2024-06-14","conditions":["Fertility"],"enrollment":310,"completionDate":"2025-09-05"},{"nctId":"NCT05499052","phase":"","title":"Trial to Assess the Pattern of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection (ICSI) Procedures in Routine Clinical Practice","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2022-08-28","conditions":["Controlled Ovarian Stimulation"],"enrollment":201,"completionDate":"2024-03-14"},{"nctId":"NCT06511791","phase":"PHASE1","title":"An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta at Different Time Intervals During Controlled Ovarian Stimulation.","status":"TERMINATED","sponsor":"Ferring Pharmaceuticals","startDate":"2024-07-15","conditions":["Infertility"],"enrollment":106,"completionDate":"2025-09-05"},{"nctId":"NCT06879002","phase":"","title":"Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol","status":"NOT_YET_RECRUITING","sponsor":"ART Fertility Clinics LLC","startDate":"2025-12-30","conditions":["Stimulation in the Ovary","IVF Outcome"],"enrollment":252,"completionDate":"2026-12-30"},{"nctId":"NCT06193135","phase":"NA","title":"Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitary Suppression With Medroxiprogesterona Acetate (MPA)","status":"RECRUITING","sponsor":"Instituto Valenciano de Infertilidad, IVI VALENCIA","startDate":"2025-07-08","conditions":["Infertility, Female","Reproductive Sterility"],"enrollment":318,"completionDate":"2025-12-31"},{"nctId":"NCT07148921","phase":"","title":"Perception of Pain During Gender Affirming Hormone Therapy","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-12-01","conditions":["Transgender Persons","Pain Threshold","Perception of Pain","Sex Hormones"],"enrollment":40,"completionDate":"2026-03"},{"nctId":"NCT07128394","phase":"NA","title":"Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment","status":"RECRUITING","sponsor":"Nanjing University","startDate":"2024-02-01","conditions":["Infertility, Female","Luteinizing Hormone (LH)"],"enrollment":590,"completionDate":"2026-11-30"},{"nctId":"NCT07121751","phase":"PHASE4","title":"Optimal Stimulation of Hypo-responders Undergoing in Vitro Fertilization (IVF)","status":"NOT_YET_RECRUITING","sponsor":"Dunamenti REK Istenhegyi IVF Center","startDate":"2025-09-01","conditions":["Hypo-responder","Infertility (IVF Patients)","OVARIAN STIMULATION"],"enrollment":150,"completionDate":"2027-03-01"},{"nctId":"NCT07117682","phase":"NA","title":"Safety and Efficacy of Autologous Adipose-Derived Regenerative Cells (ADRCs) Injection for Improving Diminished Ovarian Reserve","status":"NOT_YET_RECRUITING","sponsor":"Cytori Therapeutics","startDate":"2025-08-25","conditions":["Diminished Ovarian Reserve (DOR)","Primary Ovarian Insufficiency (Poi)","Ovarian Failure, Premature"],"enrollment":25,"completionDate":"2027-08-01"},{"nctId":"NCT05379556","phase":"","title":"LOng COvid COmorbidities: Andrological, Reproductive, Sexual Dysfunctions in Patients Recovered From COVID-19","status":"RECRUITING","sponsor":"Federico II University","startDate":"2022-01-27","conditions":["Long Covid-19"],"enrollment":100,"completionDate":"2027-01-27"},{"nctId":"NCT05293366","phase":"","title":"LOng COvid COmorbidities: Endocrine,Metabolic,Neuropsychiatric,Muscle,Cardiovascular,Pulmonary,Dermatologic Dysfunctions","status":"RECRUITING","sponsor":"Federico II University","startDate":"2022-01-27","conditions":["Long Covid-19"],"enrollment":100,"completionDate":"2027-01-27"},{"nctId":"NCT05753254","phase":"NA","title":"Effect on Markers of Cardiovascular, Reproductive and Cancer Risk From Firefighting Training","status":"COMPLETED","sponsor":"National Research Centre for the Working Environment, Denmark","startDate":"2023-03-10","conditions":["Reactive Hyperemia","Micro RNA","Heart Rate Variability","DNA Strand Breaks","Oxidative Stress","Heat Stress"],"enrollment":35,"completionDate":"2024-07-05"},{"nctId":"NCT06936930","phase":"","title":"Reproductive and Mental Health of Patients With Aplastic Anemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-03","conditions":["Aplastic Anemia","Reproductive Health"],"enrollment":600,"completionDate":"2027-12-31"},{"nctId":"NCT06997900","phase":"PHASE2","title":"Menopur And Rekovelle Combination Study Version 2.0","status":"RECRUITING","sponsor":"Clinique Ovo","startDate":"2025-07-04","conditions":["IVF","Controlled Ovarian Simulation","Fertility Disorders"],"enrollment":200,"completionDate":"2027-08"},{"nctId":"NCT06995261","phase":"","title":"Follitropin Delta in Long GnRH-agonist Protocol","status":"RECRUITING","sponsor":"Prof. Dr. med. M.Sc. Georg Griesinger","startDate":"2025-07-09","conditions":["Infertility (IVF Patients)","Infertility","Infertility Drugs"],"enrollment":350,"completionDate":"2027-12"},{"nctId":"NCT06732843","phase":"","title":"Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of Cumulus Cells During Antral Follicle Growth and Impact Blastocyst Status?","status":"RECRUITING","sponsor":"ART Fertility Clinics LLC","startDate":"2025-07-23","conditions":["OVARIAN STIMULATION","Telomere Length","Telomere Length, Mean Leukocyte"],"enrollment":10,"completionDate":"2027-07-31"},{"nctId":"NCT06978504","phase":"NA","title":"Impact of Genetic Polymorphisms And DASH Diet On Weight Loss Progression In Climacteric Women With Metabolic Syndrome","status":"RECRUITING","sponsor":"Nutrindo Ideais Research Center","startDate":"2025-04-01","conditions":["Nutrition","Metabolic Syndrome","Obesity","Weight Loss","Genetic Polymorphisms"],"enrollment":30,"completionDate":"2025-10-30"},{"nctId":"NCT05815719","phase":"PHASE4","title":"Continuous Double Ovarian Stimulation.","status":"COMPLETED","sponsor":"Instituto Bernabeu","startDate":"2022-11-17","conditions":["Fertility Issues"],"enrollment":30,"completionDate":"2023-05-30"},{"nctId":"NCT06921395","phase":"PHASE4","title":"Phase IV Study to Evaluate the Efficacy and Safety of Fang Le Shu Compared to Guo Na Fen for Controlled Ovarian Stimulation in Infertile Women Undergoing in Vitro Fertilization-embryo Transfer (IVF-ET).","status":"RECRUITING","sponsor":"LG Chem","startDate":"2025-02-15","conditions":["Female Infertility"],"enrollment":248,"completionDate":"2026-06-30"},{"nctId":"NCT05263388","phase":"PHASE3","title":"A Trial to Compare the Ovarian Response of REKOVELLE and GONAL-F in Conventional Dosing in Women Undergoing Controlled Ovarian Stimulation","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2022-07-15","conditions":["Infertility"],"enrollment":302,"completionDate":"2024-04-16"},{"nctId":"NCT04654039","phase":"","title":"Post-Marketing Surveillance (PMS) Protocol of REKOVELLE Pre-Filled Pen (Follitropin Delta)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2020-10-26","conditions":["Infertility, Female"],"enrollment":728,"completionDate":"2023-10-28"},{"nctId":"NCT04202094","phase":"NA","title":"Fertility in Young Adults Who Did (Not) Store Testicular Tissue Before a Treatment Leading to Fertility Problems","status":"ENROLLING_BY_INVITATION","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2020-09-08","conditions":["Childhood Cancer","Hematological Disorders"],"enrollment":50,"completionDate":"2030-12"},{"nctId":"NCT05173597","phase":"","title":"Real-world Evidence on Follitropin Delta Individual Dosing","status":"RECRUITING","sponsor":"University of Luebeck","startDate":"2021-12-08","conditions":["Infertility","Sterility"],"enrollment":850,"completionDate":"2026-03"},{"nctId":"NCT03737253","phase":"NA","title":"Hormone Evaluation in Artificial Reproductive Technology","status":"COMPLETED","sponsor":"Lund University","startDate":"2016-09","conditions":["Female Infertility"],"enrollment":810,"completionDate":"2024-10-02"},{"nctId":"NCT06154083","phase":"PHASE4","title":"INtensity of OVarian Stimualtion and Euploid Embryos","status":"RECRUITING","sponsor":"Fundación Santiago Dexeus Font","startDate":"2023-12-12","conditions":["Fertility"],"enrollment":110,"completionDate":"2026-05-15"},{"nctId":"NCT06635538","phase":"NA","title":"One-shot Ovarian Stimulation Protocol (One-shot)","status":"RECRUITING","sponsor":"Fundación Santiago Dexeus Font","startDate":"2024-10-31","conditions":["Infertility, Female"],"enrollment":20,"completionDate":"2025-04"},{"nctId":"NCT06618703","phase":"NA","title":"Brain Irradiation for Childhood Cancer - Endocrine Monitoring During the First Years","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Angers","startDate":"2025-03","conditions":["Endocrine; Deficiency","Hypothalamo-Pituitary Disorder","Radiotherapy Side Effect"],"enrollment":230,"completionDate":"2030-10"},{"nctId":"NCT06572930","phase":"","title":"Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation","status":"RECRUITING","sponsor":"ART Fertility Clinics LLC","startDate":"2024-12-16","conditions":["Ovarian Stimulation"],"enrollment":150,"completionDate":"2025-12-01"},{"nctId":"NCT06418347","phase":"PHASE3","title":"Effect of ALA Combined With Letrozole on Polycystic Ovary Syndrome Clinical Outcome in Infertile Females","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2024-04-01","conditions":["Polycystic Ovary Syndrome","Infertility, Female"],"enrollment":150,"completionDate":"2025-12-01"},{"nctId":"NCT04445025","phase":"EARLY_PHASE1","title":"Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With Endometriosis","status":"COMPLETED","sponsor":"Colorado Center for Reproductive Medicine","startDate":"2020-09-01","conditions":["Infertility","Endometriosis"],"enrollment":30,"completionDate":"2024-12-30"},{"nctId":"NCT06806501","phase":"","title":"Muscle Mass, Quality, and the Menopause: Sex-specific Strategies to Mitigate Sarcopenia in Ageing Populations","status":"RECRUITING","sponsor":"University of Nottingham","startDate":"2024-07-29","conditions":["Healthy"],"enrollment":18,"completionDate":"2026-03"},{"nctId":"NCT06803199","phase":"NA","title":"Effects of LH and FSH on Metabolic Regulation in Cumulus Cells","status":"RECRUITING","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2024-12-01","conditions":["Unrecognized Condition"],"enrollment":60,"completionDate":"2027-12-31"},{"nctId":"NCT03976544","phase":"PHASE4","title":"Natural Cycle Versus Hormone Replacement Therapy Cycle for a Frozen-thawed Embryo Transfer in PGT Patients","status":"TERMINATED","sponsor":"CRG UZ Brussel","startDate":"2019-05-25","conditions":["Miscarriage","Frozen Embryo Transfer","Natural Cycle","Hormone Replacement Therapy Cycle","Preimplantation Genetic Screening","Euploid Embryos"],"enrollment":362,"completionDate":"2025-01-01"},{"nctId":"NCT04773353","phase":"PHASE3","title":"Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Indian Women","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2021-12-03","conditions":["Infertility"],"enrollment":220,"completionDate":"2023-12-12"},{"nctId":"NCT06778733","phase":"EARLY_PHASE1","title":"Effectiveness of Low Dose Gonadotropin Stimulation Protocol Vs High Dose Gonadotropin Protocol in Poor Responders","status":"COMPLETED","sponsor":"University of Athens","startDate":"2022-01-01","conditions":["Female Infertility"],"enrollment":22,"completionDate":"2024-04-30"},{"nctId":"NCT06778304","phase":"PHASE1","title":"Bioequivalence Clinical Trial of Recombinant Human Follicle-stimulating Hormone JZB30","status":"COMPLETED","sponsor":"West China Second University Hospital","startDate":"2021-01-04","conditions":["Bioequivalence","Healthy Volunteers","Pharmacokinetics","Safety","Immunogenicity"],"enrollment":48,"completionDate":"2022-01-17"},{"nctId":"NCT05330130","phase":"PHASE1","title":"Impact of FSH Dosage During Ovarian Stimulation for IVF/ICSI in Granulosa Cells","status":"COMPLETED","sponsor":"ART Fertility Clinics LLC","startDate":"2023-07-05","conditions":["Ovarian Function Insufficiency","Fertility Issues","Infertility,Female","Infertility"],"enrollment":6,"completionDate":"2024-06-30"},{"nctId":"NCT04997525","phase":"PHASE4","title":"Estradiol and Progesterone Levels Following Frozen Embryo Transfer","status":"COMPLETED","sponsor":"Copenhagen University Hospital at Herlev","startDate":"2021-04-20","conditions":["Infertility"],"enrollment":305,"completionDate":"2024-12-06"},{"nctId":"NCT05103228","phase":"NA","title":"Cumulative Pregnancy Rate With Lower and Higher Gonadotropin Dose During IVF Among Poor Responders","status":"COMPLETED","sponsor":"Peter Kovacs MD","startDate":"2021-12-02","conditions":["Infertility","Ovarian Dysfunction"],"enrollment":190,"completionDate":"2023-07-20"},{"nctId":"NCT06729359","phase":"","title":"Polycystic Ovary Syndrome and Urinary Tract Stones: a BMI-Adjusted Analysis in Iraqi Women","status":"COMPLETED","sponsor":"Al-Kindy College of Medicine","startDate":"2024-07-01","conditions":["PCOS (Polycystic Ovary Syndrome)","Stone, Urinary","BMI","Obesity","Overweight","Underweight"],"enrollment":407,"completionDate":"2024-11-15"},{"nctId":"NCT06091436","phase":"PHASE3","title":"To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference","status":"COMPLETED","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2023-03-24","conditions":["Infertility"],"enrollment":176,"completionDate":"2024-01-29"},{"nctId":"NCT06095206","phase":"PHASE1","title":"The Pharmacokinetic and Bioavailability of GenSci094 Before and After a Change in Manufacturing Site","status":"COMPLETED","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2023-09-19","conditions":["Infertility"],"enrollment":48,"completionDate":"2023-11-13"},{"nctId":"NCT06414096","phase":"PHASE1","title":"Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-10-01","conditions":["Infertility","Obesity"],"enrollment":5,"completionDate":"2026-11"},{"nctId":"NCT04285892","phase":"NA","title":"Embryo Developmental Potential in a Novel 2-step IVM System","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2020-07-16","conditions":["In Vitro Maturation of Oocytes"],"enrollment":23,"completionDate":"2023-12-31"},{"nctId":"NCT05403476","phase":"PHASE2","title":"A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained Reduction of Semen Quality) (ADAM)","status":"TERMINATED","sponsor":"Ferring Pharmaceuticals","startDate":"2022-08-16","conditions":["Male Idiopathic Infertility"],"enrollment":4,"completionDate":"2024-10-23"},{"nctId":"NCT05936840","phase":"","title":"Quantum Menstrual Health Monitoring Study","status":"RECRUITING","sponsor":"Quanovate Tech Inc.","startDate":"2024-05-01","conditions":["Menstrual Cycle Abnormal","Polycystic Ovary Syndrome","Athletes"],"enrollment":150,"completionDate":"2026-05-01"},{"nctId":"NCT00703014","phase":"","title":"Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05787 (P05712)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-07-13","conditions":["Pregnancy","Neonates"],"enrollment":541,"completionDate":"2009-03-15"},{"nctId":"NCT00702338","phase":"","title":"Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05693 (P05713)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-05-15","conditions":["Pregnancy","Neonates"],"enrollment":1,"completionDate":"2008-12-15"},{"nctId":"NCT00702520","phase":"","title":"Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-04-01","conditions":["Pregnancy","Neonates"],"enrollment":15,"completionDate":"2008-01-15"},{"nctId":"NCT00702273","phase":"","title":"Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Trial P05787 (P05716)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-04-19","conditions":["In Vitro Fertilization"],"enrollment":344,"completionDate":"2009-05-31"},{"nctId":"NCT00702234","phase":"","title":"Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care Program)(P05715)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-02-15","conditions":["Pregnancy","Neonates"],"enrollment":268,"completionDate":"2010-01-15"},{"nctId":"NCT06571214","phase":"PHASE4","title":"Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment","status":"NOT_YET_RECRUITING","sponsor":"Nanjing University","startDate":"2024-09-01","conditions":["Infertility"],"enrollment":300,"completionDate":"2027-01-30"},{"nctId":"NCT06561594","phase":"PHASE3","title":"To Evaluate Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for Injection","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2024-09-20","conditions":["Idiopathic Hypogonadotropic Hypogonadism"],"enrollment":60,"completionDate":"2026-12-23"},{"nctId":"NCT00598208","phase":"PHASE2","title":"A Phase 2, Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian (Study 38826)(P06055)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-05-19","conditions":["Fertilization"],"enrollment":325,"completionDate":"2004-03-15"},{"nctId":"NCT00702585","phase":"PHASE2","title":"Study to Investigate the Optimal Dose of Org 36286 to Induce Monofollicular Ovulation in Women With WHO Group II Anovulatory Infertility (P07016)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-08-01","conditions":["Infertility"],"enrollment":55,"completionDate":"2002-10-15"},{"nctId":"NCT00702806","phase":"PHASE2","title":"Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI (P07015)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-07-01","conditions":["Infertility","In Vitro Fertilization"],"enrollment":99,"completionDate":"2002-10-15"},{"nctId":"NCT00702195","phase":"","title":"Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established During Phase II Clinical Trials of Org 36286 (Study 38817)(P06054)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-01-01","conditions":["Pregnancy"],"enrollment":29,"completionDate":"2003-09-15"},{"nctId":"NCT06481696","phase":"NA","title":"Possible Action of Resveratrol in Improving the Outcomes of IVF/ICSI in Couples With Unexplained Infertility","status":"RECRUITING","sponsor":"Andros Day Surgery Clinic","startDate":"2024-06-01","conditions":["Unexplained Infertility"],"enrollment":90,"completionDate":"2025-12-31"},{"nctId":"NCT06480682","phase":"","title":"Relative Energy Deficiency in Sport and Dance","status":"NOT_YET_RECRUITING","sponsor":"University of Wolverhampton","startDate":"2024-09-10","conditions":["Relative Energy Deficiency in Sport","Bone Stress Reaction"],"enrollment":200,"completionDate":"2029-07-30"},{"nctId":"NCT00696800","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-06-27","conditions":["In Vitro Fertilization"],"enrollment":1509,"completionDate":"2008-01-15"},{"nctId":"NCT01146418","phase":"PHASE3","title":"Frozen-thawed Embryo Transfer (FTET) Cycle Follow-up Protocol (P06031)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-06-02","conditions":["Infertility"],"enrollment":307,"completionDate":"2014-04-29"},{"nctId":"NCT00702845","phase":"PHASE3","title":"To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-12-28","conditions":["Infertility"],"enrollment":397,"completionDate":"2007-11-15"},{"nctId":"NCT00696878","phase":"PHASE3","title":"Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09-26","conditions":["In Vitro Fertilization"],"enrollment":682,"completionDate":"2009-05-15"},{"nctId":"NCT00697255","phase":"PHASE2","title":"A Phase 2 Trial to Evaluate if Corifollitropin Alfa (Org 36286), Followed by a Low Daily Dose of hCG or Recombinant FSH Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility (P05693)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2007-05-15","conditions":["Ovulation Induction"],"enrollment":8,"completionDate":"2008-05-15"},{"nctId":"NCT01421095","phase":"NA","title":"Ovarian Reserve Testing in Female Young Adult Cancer Survivors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2011-01-01","conditions":["Cancer","Infertility"],"enrollment":34,"completionDate":"2026-12"},{"nctId":"NCT02478775","phase":"NA","title":"Dysregulation of FSH in Obesity: Functional and Statistical Analysis","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2015-07","conditions":["Obesity","Fertility"],"enrollment":99,"completionDate":"2021-06-30"},{"nctId":"NCT01709331","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-02-11","conditions":["Hypogonadism","Hypogonadotropic Hypogonadism"],"enrollment":18,"completionDate":"2015-04-08"},{"nctId":"NCT03019575","phase":"PHASE3","title":"Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2017-02-02","conditions":["Hypogonadotropic Hypogonadism"],"enrollment":17,"completionDate":"2020-05-05"},{"nctId":"NCT04695483","phase":"PHASE4","title":"Reduction of Progesterone Elevation at Trigger in POR After Long Acting COS Compared With Daily COS: a Prospective Randomized Trial","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2022-02-22","conditions":["Infertility"],"enrollment":110,"completionDate":"2024-05-06"},{"nctId":"NCT03809429","phase":"PHASE3","title":"Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2019-04-29","conditions":["Infertility, Female"],"enrollment":437,"completionDate":"2022-02-16"},{"nctId":"NCT04487925","phase":"PHASE4","title":"Controlled Ovarian Stimulation Versus Modified Natural Cycles in Poor Responders","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2022-01-25","conditions":["Ovarian Reserve","Poor Responders","IVF"],"enrollment":208,"completionDate":"2024-12-31"},{"nctId":"NCT06395623","phase":"","title":"Study of Acupoints in Diminished Ovarian Reserve Based on Biological Characteristics","status":"RECRUITING","sponsor":"Xiaomei Shao","startDate":"2024-03-24","conditions":["Diminished Ovarian Reserve"],"enrollment":100,"completionDate":"2025-12-30"},{"nctId":"NCT05405686","phase":"PHASE4","title":"Effect of LH Supplementation on the Endometrial Gene Expression Profile in Poor Ovarian Responders","status":"WITHDRAWN","sponsor":"CRG UZ Brussel","startDate":"2023-05-01","conditions":["Poor Response to Ovulation Induction"],"enrollment":0,"completionDate":"2024-08-01"},{"nctId":"NCT05521828","phase":"NA","title":"Luteal Phase Ovarian Stimulation With Follitropin Delta and Dydrogesterone","status":"UNKNOWN","sponsor":"CRG UZ Brussel","startDate":"2023-04-01","conditions":["Oocyte Donors","Oocyte Donation"],"enrollment":50,"completionDate":"2024-12-31"},{"nctId":"NCT05670795","phase":"NA","title":"Comparison of Recombinant Follicle Stimulating Hormone and the Combination of Recombinant Follicle Stimulating Hormone With Clomiphene Citrate in Stimulated Intrauterine Insemination Cycles","status":"UNKNOWN","sponsor":"Bezmialem Vakif University","startDate":"2023-01-01","conditions":["Infertility Unexplained"],"enrollment":254,"completionDate":"2024-05-01"},{"nctId":"NCT05948293","phase":"NA","title":"FSH Doser for Controlled Ovarian Stimulation","status":"WITHDRAWN","sponsor":"Clínica EUGIN","startDate":"2024-06","conditions":["Infertility"],"enrollment":0,"completionDate":"2025-12"}],"_emaApprovals":[{"date":"1996-05-02","status":"Authorised","company":"N.V. Organon"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Subcutaneous","formulation":"Injection","formulations":[{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Follistim AQ"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Gonal-f RFF Redi-ject"}]},"crossReferences":{"NUI":"N0000147458","MMSL":"4760","NDDF":"002102","UNII":"076WHW89TW","VUID":"4019254","CHEBI":"CHEBI:81569","VANDF":"4019253","INN_ID":"9503","RXNORM":"134404","UMLSCUI":"C0733758","chemblId":"CHEMBL4297955","ChEMBL_ID":"CHEMBL4297955","KEGG_DRUG":"D06269","DRUGBANK_ID":"DB00066","PUBCHEM_CID":"62819","SNOMEDCT_US":"103028007","IUPHAR_LIGAND_ID":"1157","MESH_DESCRIPTOR_UI":"D005640","MESH_SUPPLEMENTAL_RECORD_UI":"C000620228"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","company":"EMD Serono, Inc.","brandName":"Gonal-f RFF Redi-ject","isOriginal":true,"marketingStatus":"BLA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1986-","companyName":"Serono","relationship":"Original Developer"},{"period":"1996","companyName":"N.V. Organon","relationship":"EMA Licensee"},{"period":"2006","companyName":"Serono Japan","relationship":"PMDA Licensee"}],"publicationCount":794,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"G03GA04","allCodes":["G03GA04","G03GA05","G03GA06","G03GA10"]},"biosimilarFilings":[],"originalDeveloper":"Serono","recentPublications":[{"date":"2026 Feb 27","pmid":"41901227","title":"Disulfide Bond Mapping of Follitropin Delta, a Recombinant Follicle Stimulating Hormone (rFSH), by X-Ray Crystallography.","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2026 Mar 11","pmid":"41811581","title":"Cost-Effectiveness of Follitropin Delta Compared with Follitropins Alfa and Beta in Controlled Ovarian Stimulation for Assisted Reproductive Technologies (ART) in France.","journal":"PharmacoEconomics - open"},{"date":"2026 Feb","pmid":"41328812","title":"Real-World Effectiveness and Safety of Recombinant Human Follicle-Stimulating Hormone (rhFSH) in Infertile Women undergoing Assisted Reproductive Technology (ART): A Korean Nationwide Cohort Study.","journal":"Clinical pharmacology and therapeutics"},{"date":"2025 Dec 1","pmid":"41327305","title":"A commentary on the article \"Controlled Ovarian Stimulation (COS) with follitropin delta results in higher cumulative live birth rates compared with r-hFSH alfa/beta in a large retrospectively analysed real-world data set\".","journal":"Reproductive biology and endocrinology : RB&E"},{"date":"2026 Jan 1","pmid":"41259780","title":"Correction to: Reply: Biosimilars versus the originator of follitropin alfa in ART: eyes wide shut?","journal":"Human reproduction (Oxford, England)"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Serono","companyId":"serono","modality":"Biologic","firstApprovalDate":"1986","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1986-09-18T00:00:00.000Z","mah":"SERONO","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2001-03-26T00:00:00.000Z","mah":"EMD SERONO","brand_name_local":null,"application_number":"BLA020378"},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2006-01-23T00:00:00.000Z","mah":"SERONO JAPAN","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2013-02-06T00:00:00.000Z","mah":"EMD SERONO","brand_name_local":null,"application_number":"BLA021684"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-11-15T00:00:00.000Z","mah":"ORGANON USA LLC","brand_name_local":null,"application_number":"BLA021211"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":5,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:07:28.660625+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}